Hydrocortisone - Comprehensive Research Paper

1. Summary

Hydrocortisone (cortisol) is the synthetic form of the naturally occurring glucocorticoid hormone produced by the adrenal cortex. It is the primary glucocorticoid used for physiologic replacement therapy in patients with adrenal insufficiency (Addison's disease, congenital adrenal hyperplasia, or secondary/tertiary adrenal insufficiency). Unlike other synthetic corticosteroids that are used primarily for their anti-inflammatory and immunosuppressive effects, hydrocortisone is uniquely suited for replacement therapy because it provides both glucocorticoid and mineralocorticoid activity at physiologic doses, closely mimicking endogenous cortisol.

FDA approval history: Hydrocortisone has been available for glucocorticoid replacement therapy since the 1950s. In 2024, KHINDIVI™ (hydrocortisone oral solution) was approved by the FDA as the first FDA-approved oral solution formulation for adrenal insufficiency. Also in 2024, CRENESSITY was approved as an adjunctive treatment for congenital adrenal hyperplasia.

Standard Dosing:

• Replacement dose (adults): 15-25 mg daily (midpoint 20 mg) in 2-3 divided doses
• Morning dose: One-half to two-thirds of daily dose upon waking
• Pediatric dose: 8 mg/m²/day in divided doses
• Stress dosing (adrenal crisis): 100 mg IV bolus, then 200 mg/24 hours continuous infusion or 50 mg IV every 6 hours
• Mineralocorticoid supplementation: Often requires fludrocortisone 0.05-0.2 mg daily

Pharmacokinetic Profile:

• Bioavailability: 96% (oral administration)
• Time to peak plasma concentration: 1-2 hours (oral); 66.7 minutes mean
• Half-life: 1.5-2 hours (plasma); 8-12 hours (tissue)
• Metabolism: Hepatic via CYP3A4 to 6-beta hydrocortisol, tetrahydrocortisol, cortisone, and glucuronide conjugates
• Protein binding: 90-95% (transcortin/cortisol-binding globulin)

Cost:

• Generic hydrocortisone tablets: $12-77 for 90-day supply
• Brand-name Cortef: $212-300 for 90 tablets (30-day supply at typical replacement dose)
• GoodRx discount: Reduces cost to $21-44 for generic formulations
• Insurance coverage: Widely covered by Medicare and commercial plans for replacement therapy indications

Clinical Context:

Hydrocortisone occupies a unique position in hormone replacement therapy as the only corticosteroid that provides true physiologic cortisol replacement. The Endocrine Society Guidelines recommend 15-25 mg daily as the optimal replacement dose for adrenal insufficiency, though clinical practice often uses lower doses (empirically determined mean 13.9 mg daily). Unlike prednisone or dexamethasone, which have longer half-lives and negligible mineralocorticoid activity, hydrocortisone's pharmacokinetic profile more closely approximates the physiologic circadian rhythm of endogenous cortisol secretion, making it the gold standard for replacement therapy.

Modern formulations such as dual-release hydrocortisone (Plenadren) and continuous subcutaneous hydrocortisone infusion (CSHI) aim to better mimic the physiologic cortisol circadian rhythm, potentially improving metabolic outcomes and quality of life compared to conventional immediate-release formulations given 2-3 times daily.

2. Mechanism of Action

2.1 Glucocorticoid Receptor Activation

Hydrocortisone exerts its effects primarily through binding to the cytosolic glucocorticoid receptor (GR), a member of the nuclear receptor superfamily. The mechanism involves:

1. Receptor binding: Hydrocortisone diffuses across the cell membrane (being lipophilic) and binds to the GR in the cytoplasm
2. Nuclear translocation: The hormone-receptor complex translocates to the nucleus
3. DNA binding: The complex binds to specific DNA sequences called glucocorticoid response elements (GREs) in gene promoter regions
4. Gene transcription modulation: This leads to either transactivation (increased gene expression) or transrepression (decreased gene expression) of target genes

The molecular mechanism involves both genomic (gene transcription) and non-genomic (rapid membrane effects) pathways, though the genomic pathway accounts for most therapeutic effects.

2.2 Anti-Inflammatory Effects

Hydrocortisone produces potent anti-inflammatory effects through multiple mechanisms:

Phospholipase A2 Inhibition:

• Induces synthesis of lipocortin-1 (annexin-1), a phospholipase A2 inhibitory protein
• Blocks conversion of membrane phospholipids to arachidonic acid
• Reduces production of prostaglandins, leukotrienes, and thromboxanes
• Decreases inflammatory mediator synthesis at the source

Cytokine Suppression:

• Suppresses production of multiple pro-inflammatory cytokines including:
  • Interleukins: IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8
  • Tumor necrosis factor-alpha (TNF-α)
  • Interferon-gamma (IFN-γ)
• Inhibits nuclear factor kappa-B (NF-κB) activation, a master regulator of inflammatory gene expression
• Reduces inflammatory cell infiltration and tissue damage

Immune Cell Effects:

• Inhibits lymphocyte proliferation and antibody production
• Reduces circulating eosinophils, basophils, monocytes, and lymphocytes
• Increases circulating neutrophils (demargination effect)
• Suppresses delayed-type hypersensitivity reactions

2.3 Metabolic Effects

As the primary endogenous glucocorticoid, hydrocortisone regulates multiple metabolic pathways:

Carbohydrate Metabolism:

• Stimulates hepatic gluconeogenesis (glucose production from amino acids and lactate)
• Antagonizes insulin action in peripheral tissues
• Increases blood glucose levels
• Promotes glycogen deposition in the liver

Protein Metabolism:

• Increases protein catabolism in muscle, skin, bone, and connective tissue
• Provides amino acid substrates for gluconeogenesis
• Reduces protein synthesis in peripheral tissues
• Preserves protein synthesis in liver and brain

Lipid Metabolism:

• Promotes lipolysis (fat breakdown) in adipose tissue
• Increases free fatty acid availability
• Redistributes body fat from extremities to central/truncal areas (with chronic excess)
• Elevates serum triglycerides and cholesterol

2.4 Mineralocorticoid Activity

Unlike purely synthetic glucocorticoids (prednisone, dexamethasone), hydrocortisone retains significant mineralocorticoid activity:

• Binds to mineralocorticoid receptors in the distal renal tubule
• Promotes sodium reabsorption and potassium excretion
• Contributes to blood pressure regulation and fluid balance
• Mineralocorticoid-to-glucocorticoid ratio is 1:1 for hydrocortisone
• At replacement doses (15-25 mg daily), provides partial mineralocorticoid replacement but often insufficient, requiring supplemental fludrocortisone in primary adrenal insufficiency

2.5 Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression

Exogenous hydrocortisone administration suppresses the HPA axis through negative feedback:

1. Hypothalamic suppression: Reduces corticotropin-releasing hormone (CRH) secretion
2. Pituitary suppression: Decreases adrenocorticotropic hormone (ACTH) secretion
3. Adrenal suppression: Prolonged use leads to adrenal cortex atrophy and reduced endogenous cortisol production
4. Clinical significance: Patients on chronic hydrocortisone therapy cannot mount an adequate stress response and require stress-dose coverage during illness, surgery, or trauma

The degree and duration of HPA suppression depend on dose, duration of therapy, and dosing schedule. Even replacement doses intended for physiologic cortisol restoration can suppress the HPA axis in patients with secondary or tertiary adrenal insufficiency.

2.6 Cardiovascular and Renal Effects

Hydrocortisone influences cardiovascular function through:

• Vascular tone: Maintains vascular responsiveness to catecholamines (epinephrine, norepinephrine)
• Cardiac contractility: Enhances myocardial contractility
• Blood pressure: Supports blood pressure through mineralocorticoid and permissive effects on vasopressors
• Fluid balance: Regulates electrolyte homeostasis and extracellular fluid volume

In adrenal insufficiency, cortisol deficiency leads to hypotension, hyponatremia, and hyperkalemia; hydrocortisone replacement corrects these abnormalities.

Goal Relevance:

• Manage adrenal insufficiency to improve energy levels and overall well-being
• Support recovery from adrenal crisis with effective stress dosing
• Improve quality of life for individuals with congenital adrenal hyperplasia through hormone replacement
• Enhance immune function and reduce inflammation for those with autoimmune conditions
• Mimic natural cortisol rhythms to optimize hormone balance and metabolic health
• Aid in the management of chronic fatigue related to adrenal gland disorders
• Provide a reliable option for those seeking physiologic glucocorticoid replacement therapy

3. Clinical Indications

3.1 FDA-Approved Indications

Primary Adrenal Insufficiency (Addison's Disease):

• Autoimmune destruction of the adrenal cortex (most common cause in developed countries)
• Infectious causes (tuberculosis, fungal infections, cytomegalovirus)
• Bilateral adrenal hemorrhage or infarction
• Metastatic cancer involving both adrenal glands
• Adrenalectomy (surgical removal of adrenal glands)
• Clinical presentation: Hypotension, hyperpigmentation, hyponatremia, hyperkalemia, weight loss, fatigue
• Replacement requirement: Both glucocorticoid (hydrocortisone) and mineralocorticoid (fludrocortisone) replacement

Secondary and Tertiary Adrenal Insufficiency:

• Secondary: Pituitary ACTH deficiency (pituitary tumors, surgery, radiation, Sheehan's syndrome, lymphocytic hypophysitis)
• Tertiary: Hypothalamic CRH deficiency or chronic exogenous glucocorticoid therapy suppressing the HPA axis
• Distinction from primary: Mineralocorticoid function preserved (renin-angiotensin-aldosterone system intact), so fludrocortisone typically not required
• Clinical presentation: Fatigue, weakness, hypoglycemia, hypotension (less severe than primary), no hyperpigmentation

Congenital Adrenal Hyperplasia (CAH):

• Genetic enzymatic defects in cortisol biosynthesis (most commonly 21-hydroxylase deficiency)
• Results in cortisol deficiency and ACTH-driven androgen excess
• Treatment goals: Replace deficient cortisol and suppress excessive ACTH to reduce androgen overproduction
• Pediatric considerations: Critical to avoid both under-replacement (inadequate androgen suppression, virilization) and over-replacement (growth suppression, obesity, metabolic syndrome)

Acute Adrenal Crisis:

• Life-threatening medical emergency characterized by severe cortisol deficiency
• Precipitating factors: Infection, trauma, surgery, medication non-compliance, bilateral adrenal hemorrhage
• Clinical features: Severe hypotension, shock, altered mental status, severe nausea/vomiting, abdominal pain, fever, hyponatremia, hyperkalemia, hypoglycemia
• Emergency treatment: 100 mg hydrocortisone IV bolus, then 200 mg/24 hours continuous infusion or 50 mg IV every 6 hours
• Mortality: High if untreated; excellent prognosis with prompt recognition and treatment

3.2 Off-Label and Supplementary Uses

Anti-Inflammatory Therapy:

• Short-term treatment of inflammatory conditions (dermatitis, allergic reactions)
• Typically other glucocorticoids (prednisone, methylprednisolone) preferred for anti-inflammatory indications due to longer half-life and negligible mineralocorticoid effects
• Topical formulations used extensively for dermatologic conditions

Septic Shock:

• Low-dose hydrocortisone (200 mg daily) for vasopressor-dependent septic shock
• Remains controversial; some guidelines recommend for refractory shock

Post-Adrenalectomy for Cushing's Syndrome:

• Comparison studies show hydrocortisone and prednisone both effective for post-surgical glucocorticoid replacement
• Hydrocortisone may offer advantages in patients requiring mineralocorticoid activity

Hypopituitarism:

• Replacement therapy for pituitary insufficiency affecting multiple axes
• Often combined with thyroid hormone, sex steroid, and growth hormone replacement

3.3 Physiologic Stress Dosing

Patients with adrenal insufficiency require stress-dose glucocorticoid coverage during physiologic stress to prevent adrenal crisis. The body normally increases cortisol production 5-10 fold during illness, surgery, or trauma; patients on replacement therapy cannot mount this response.

Stress Dosing Guidelines:

Minor stress (mild illness, minor dental procedures):

• Double or triple usual daily dose for 2-3 days
• Example: If usual dose is 20 mg daily, take 40-60 mg daily during illness

Moderate stress (moderate illness, fever >38°C, gastroenteritis with vomiting):

• 50-75 mg hydrocortisone daily in divided doses

Severe stress (major surgery, severe illness, labor and delivery):

• 100 mg hydrocortisone IV bolus, then 50-100 mg IV every 6-8 hours or 200 mg/24 hours continuous infusion
• Taper to usual replacement dose over 2-3 days as stress resolves

Patient education on stress dosing is critical to preventing adrenal crises. Patients should carry medical alert identification and injectable hydrocortisone for emergencies.

4. Dosing and Administration

4.1 Dosing for Adrenal Insufficiency (Replacement Therapy)

Adults:

Initial and Maintenance Dosing:

• Recommended dose range: 15-25 mg daily (Endocrine Society Guidelines recommend midpoint of 20 mg)
• Empiric practice: Clinical studies show mean actual dose of 13.9 ± 6 mg daily, significantly lower than guideline recommendations
• Dosing schedule: Divided into 2-3 doses daily to approximate circadian cortisol rhythm
  • Morning dose (upon waking): 10-15 mg (one-half to two-thirds of total daily dose)
  • Early afternoon dose: 5 mg (6-8 hours after morning dose)
  • Optional evening dose: 2.5-5 mg if using three-times-daily regimen (not recommended by all experts due to potential sleep interference)

Rationale for Divided Dosing:

• Endogenous cortisol secretion follows a circadian rhythm with peak levels in early morning (8 AM) and nadir at midnight
• Immediate-release hydrocortisone has a short plasma half-life (1.5-2 hours), requiring multiple daily doses
• Larger morning dose mimics the physiologic cortisol peak
• Avoids late evening doses that may suppress endogenous HPA axis overnight (in secondary/tertiary insufficiency) and interfere with sleep

Dose Titration:

• Monitor clinical symptoms (energy, blood pressure, weight)
• Assess for signs of under-replacement (fatigue, hypotension, weight loss) or over-replacement (weight gain, hyperglycemia, hypertension, fluid retention)
• Adjust dose in 2.5-5 mg increments based on response
• Some patients require as little as 10-15 mg daily; others may need 30-37.5 mg daily

Mineralocorticoid Supplementation (Primary Adrenal Insufficiency Only):

• Hydrocortisone provides partial mineralocorticoid activity but usually insufficient at replacement doses
• Add fludrocortisone 0.05-0.2 mg daily (typical dose 0.1 mg)
• Monitor blood pressure, serum sodium, and potassium
• Renin levels can guide fludrocortisone dosing (goal: upper normal range)

Pediatric Dosing:

Standard Replacement:

• Dose: 8 mg/m²/day divided into 3 doses
• Alternative weight-based: 10-15 mg/m²/day for infants and young children
• Dosing schedule:
  • Morning: 50% of daily dose
  • Midday: 25% of daily dose
  • Evening: 25% of daily dose

Congenital Adrenal Hyperplasia (CAH):

• Higher doses may be required to suppress ACTH-driven androgen production
• Typical range: 10-20 mg/m²/day
• Balance androgen suppression against growth suppression risk
• Monitor 17-hydroxyprogesterone and androstenedione levels

Infants and Neonates:

• May require higher doses per body surface area due to increased metabolic clearance
• Liquid formulations (suspension, compounded solution) facilitate accurate dosing
• FDA-approved oral solution (KHINDIVI) now available for precise pediatric dosing

4.2 Modified-Release Formulations

Dual-Release Hydrocortisone (Plenadren®):

• Formulation: Immediate-release outer layer + delayed-release core
• Dosing: Once-daily administration in the morning (5-40 mg range)
• Bioavailability: Approximately 20% lower than conventional hydrocortisone; dose adjustment required
• Pharmacokinetics: Achieves morning cortisol peak within 1 hour, followed by second peak 6-8 hours later
• Conversion: If patient on conventional hydrocortisone 20 mg daily, start Plenadren 15-20 mg once daily
• Clinical evidence: Crossover study showed modest improvements in blood pressure and weight

Chronocort® (under investigation):

• Delayed- and sustained-release formulation designed for bedtime administration
• Aims to replicate overnight cortisol rise more physiologically
• Not yet FDA-approved in the United States

Continuous Subcutaneous Hydrocortisone Infusion (CSHI):

• Administered via insulin pump with adjustable delivery rate
• Allows precise circadian rhythm replication
• Reserved for patients with difficult-to-control symptoms or frequent adrenal crises on oral therapy
• Requires specialized training and close monitoring

4.3 Dosing for Stress Coverage

Minor Stress (Mild Febrile Illness, Minor Dental Work):

• Double usual daily dose for duration of illness (typically 2-3 days)
• Example: Usual dose 20 mg daily → 40 mg daily during illness
• Return to usual dose when stress resolves

Moderate Stress (Gastroenteritis with Vomiting, Fever >38.5°C, Minor Surgery Under Local Anesthesia):

• 50-75 mg hydrocortisone daily in divided doses
• If unable to take oral medication due to vomiting: 50-100 mg IM/IV hydrocortisone
• Consider hospitalization if unable to maintain oral intake or symptoms persist

Major Stress (Severe Illness, Major Surgery, Trauma, Labor and Delivery):

• Adrenal crisis protocol: 100 mg hydrocortisone IV bolus stat
• Maintenance during stress: 200 mg/24 hours via continuous IV infusion OR 50 mg IV every 6 hours
• Taper: Reduce by 50% daily as clinical condition improves until usual replacement dose reached

Surgical Stress:

• Minor surgery (local anesthesia, <1 hour): 25 mg IV hydrocortisone at induction
• Moderate surgery (e.g., cholecystectomy, hernia repair): 50-75 mg IV hydrocortisone at induction, then 50 mg every 8-12 hours for 24 hours
• Major surgery (e.g., cardiac surgery, major abdominal surgery): 100 mg IV hydrocortisone at induction, then 50 mg IV every 6-8 hours for 48-72 hours

4.4 Administration Guidelines

Timing:

• Take the largest dose immediately upon waking (before getting out of bed if possible) to mimic cortisol awakening response
• Second dose 6-8 hours later (early afternoon, typically 2-4 PM)
• If using three-times-daily regimen, third dose no later than 6 PM to avoid sleep interference

With or Without Food:

• Hydrocortisone can be taken with or without food
• Taking with food may reduce GI upset in sensitive individuals
• Bioavailability not significantly affected by food

Missed Dose:

• If dose missed and remembered within 2-3 hours: take immediately
• If close to next scheduled dose: skip missed dose and resume regular schedule
• Never double dose to make up for a missed dose
• If multiple doses missed or vomiting prevents oral intake: seek medical attention for parenteral administration

Tablet Formulations:

• Available as 5 mg, 10 mg, 20 mg tablets
• Can be split for dose adjustments (e.g., 2.5 mg, 7.5 mg increments)

Liquid Formulations:

• KHINDIVI oral solution: 5 mg/mL concentration
• Compounded suspensions available for pediatric use
• Allows precise dosing in infants and children

Parenteral Formulations:

• Hydrocortisone sodium succinate for IV/IM injection (Solu-Cortef®)
• Available as 100 mg, 250 mg, 500 mg, 1000 mg vials
• Reconstitute with sterile water or normal saline
• Store reconstituted solution at room temperature 20-25°C and use within 12 hours if kept at room temperature or 24 hours if refrigerated

4.5 Special Dosing Considerations

Elderly:

• Start at lower end of dosing range (15 mg daily)
• Increased risk of corticosteroid-related adverse effects (osteoporosis, hyperglycemia, hypertension)
• Monitor bone density and glucose tolerance

Renal Impairment:

• No specific dose adjustment required
• Monitor fluid and electrolyte balance closely

Hepatic Impairment:

• Hydrocortisone metabolism reduced in severe liver disease
• May require dose reduction
• Monitor for signs of glucocorticoid excess

Pregnancy:

• Adrenal insufficiency must be treated during pregnancy to prevent maternal and fetal complications
• Usual replacement doses continued throughout pregnancy
• Stress-dose coverage required during labor and delivery: 100 mg IV hydrocortisone at onset of active labor, then 50 mg IV every 6 hours until delivery
• See Section 9.1 for detailed pregnancy considerations

Obesity:

• Dosing based on body surface area (mg/m²) rather than total body weight may be more appropriate
• Avoid excessive dosing based on total weight, which can lead to Cushingoid features
• Ideal body weight or lean body mass should guide dosing adjustments

Drug Interactions Affecting Dosing:

• CYP3A4 inducers (phenytoin, rifampin, phenobarbital): May increase hydrocortisone metabolism, requiring dose increase of 50-100%
• CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir): May decrease hydrocortisone metabolism, potentially requiring dose reduction
• See Section 7 for comprehensive drug interaction discussion

5. Pharmacokinetics

5.1 Absorption

Oral Administration:

Hydrocortisone demonstrates excellent oral bioavailability averaging 96%, with some studies reporting nearly 100% absorption. Absorption is rapid, with maximum plasma concentrations achieved 1-2 hours after oral administration. More detailed pharmacokinetic studies found mean time to maximum concentration (tmax) of 66.7 minutes (range 20-118 minutes), with cortisol concentrations rising rapidly within 30 minutes following oral hydrocortisone administration.

Factors Affecting Absorption:

• Food: Bioavailability not significantly affected by food intake; hydrocortisone can be taken with or without meals
• Gastric pH: Unlike some medications, hydrocortisone absorption is not meaningfully altered by proton pump inhibitors or H2 blockers
• Gastrointestinal disease: Malabsorption syndromes (celiac disease, inflammatory bowel disease) may reduce absorption; monitor clinical response and consider dose adjustment

Alternative Routes:

• Topical (cream/ointment): Bioavailability 4-19% depending on formulation, application site, skin integrity, and occlusion
• Rectal (enema): Bioavailability 0.502 for rapid absorbers and 0.810 for slow absorbers
• Intramuscular/Intravenous: 100% bioavailability by definition

5.2 Distribution

Volume of Distribution:

• Total body clearance: 18 L/hr
• Volume of distribution: 34 L (approximately 0.5 L/kg in a 70 kg adult)
• Distributes readily into most body tissues due to lipophilic nature

Protein Binding:

• Total binding: 90-95% of circulating hydrocortisone is protein-bound
• Transcortin (cortisol-binding globulin, CBG): Binds approximately 80% of cortisol with high affinity but low capacity
• Albumin: Binds approximately 10-15% with low affinity but high capacity
• Free (unbound) fraction: 5-10% represents the biologically active portion

Clinical Significance of Protein Binding:

• Conditions that reduce CBG (nephrotic syndrome, liver disease, hyperthyroidism) increase free cortisol fraction, potentially enhancing glucocorticoid effects
• Estrogen therapy and pregnancy increase CBG levels, reducing free cortisol fraction
• Only free (unbound) cortisol can cross cell membranes and exert biologic effects
• Total hydrocortisone via oral route has a half-life of 2.15 hours while the free fraction has a half-life of 1.39 hours

Placental Transfer:

• Hydrocortisone readily crosses the placenta
• Maternal-to-fetal cortisol gradient maintained by placental 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), which converts cortisol to inactive cortisone
• Despite placental inactivation, high-dose maternal corticosteroids can expose the fetus to significant glucocorticoid levels

Blood-Brain Barrier:

• Hydrocortisone crosses the blood-brain barrier
• Central nervous system effects include mood changes, cognitive effects, and regulation of stress response

5.3 Metabolism

Hydrocortisone undergoes extensive hepatic metabolism through multiple pathways:

Primary Metabolic Pathways:

1. Reduction:

   • Hepatic reduction produces 5-beta tetrahydrocortisol and 5-alpha tetrahydrocortisol
   • These metabolites are pharmacologically inactive

2. Oxidation via CYP3A4:

   • Hydrocortisone is metabolized to 6-beta hydrocortisol via CYP3A4
   • CYP3A4 is the major cytochrome P450 enzyme involved
   • Subject to enzyme induction and inhibition (see Section 7)

3. Reversible Conversion to Cortisone:

   • 11β-hydroxysteroid dehydrogenase (11β-HSD) enzymes interconvert cortisol ↔ cortisone
   • 11β-HSD type 1: Reductase activity (cortisone → cortisol), expressed in liver, adipose, brain
   • 11β-HSD type 2: Oxidase activity (cortisol → cortisone), expressed in kidney, placenta, colon
   • Cortisone is less potent than cortisol; requires reconversion to cortisol for full activity

4. Conjugation:

   • Tetrahydrocortisol and tetrahydrocortisone undergo glucuronidation
   • Glucuronide conjugates are water-soluble and excreted in urine

Interindividual Variability:

• Mean half-life demonstrates significant variation: 76.5 ± 5.2 minutes (range 40-225.3 minutes)
• Genetic polymorphisms in CYP3A4 and 11β-HSD enzymes contribute to variability
• Clinical implication: Some patients may require higher or lower doses to achieve equivalent cortisol exposure

5.4 Elimination

Half-Life:

• Plasma half-life: 1.5-2 hours after IV administration; 1.7 hours mean
• Oral administration: Total hydrocortisone half-life 2.15 hours; free fraction half-life 1.39 hours
• Tissue half-life: 8-12 hours (explains prolonged biologic effects despite short plasma half-life)
• Biologic half-life (duration of HPA suppression): 8-12 hours

Routes of Excretion:

• Renal: Primary route; metabolites excreted as glucuronide and sulfate conjugates in urine
• Fecal: Minimal contribution
• Unchanged drug: Less than 1% excreted unchanged in urine

Effect of Renal Impairment:

• Hydrocortisone clearance not significantly affected by renal dysfunction
• Metabolites may accumulate but are inactive
• No dose adjustment required for renal impairment

Effect of Hepatic Impairment:

• Severe liver disease may reduce hydrocortisone metabolism
• Decreased clearance may necessitate dose reduction
• Monitor for signs of glucocorticoid excess (hyperglycemia, hypertension, fluid retention)

5.5 Pharmacokinetic Drug Interactions

CYP3A4 Inducers:

• Phenytoin, carbamazepine, phenobarbital, rifampin, St. John's wort
• Increase hydrocortisone metabolism, reducing plasma concentrations
• May require 50-100% dose increase to maintain therapeutic effect

CYP3A4 Inhibitors:

• Ketoconazole, itraconazole, ritonavir, clarithromycin, grapefruit juice
• Decrease hydrocortisone metabolism, increasing plasma concentrations
• Risk of glucocorticoid excess; consider dose reduction if prolonged co-administration

Hydrocortisone as CYP3A4 Inducer:

• Hydrocortisone itself induces CYP3A4 at pharmacologic (supraphysiologic) doses
• Can reduce plasma concentrations of CYP3A4 substrates (e.g., cyclosporine, tacrolimus, certain statins)

6. Side Effects and Safety Profile

6.1 Common Side Effects (Occur with Over-Replacement)

At physiologic replacement doses (15-25 mg daily), hydrocortisone is generally well-tolerated with minimal adverse effects. However, even slight over-replacement or pharmacologic doses produce dose-related side effects:

Metabolic Effects:

• Hyperglycemia: Impaired glucose tolerance, insulin resistance, new-onset diabetes
• Weight gain: Increased appetite, central adiposity
• Dyslipidemia: Elevated triglycerides and LDL cholesterol
• Fluid retention: Sodium retention, edema (mineralocorticoid effect)

Musculoskeletal Effects:

• Osteoporosis: Reduced bone mineral density, increased fracture risk
• Myopathy: Proximal muscle weakness (especially with long-term use)
• Avascular necrosis: Osteonecrosis of femoral/humoral head (rare, dose-related)
• Growth retardation in children: Suppression of longitudinal bone growth

Cardiovascular Effects:

• Hypertension: Sodium retention and increased vascular sensitivity to catecholamines
• Atherosclerosis: Accelerated cardiovascular disease with chronic excess

Dermatologic Effects:

• Skin thinning: Striae, easy bruising, delayed wound healing
• Acne: Glucocorticoid-induced acne
• Hirsutism: Increased facial/body hair (mild androgenic effects)

Gastrointestinal Effects:

• Peptic ulcer disease: Increased risk, especially with NSAIDs or anticoagulants
• GI bleeding: 4-fold increased risk when combined with NSAIDs
• Pancreatitis: Rare but serious complication

Ophthalmic Effects:

• Cataracts: Posterior subcapsular cataracts with prolonged use
• Glaucoma: Increased intraocular pressure
• Exophthalmos: Rare

6.2 Serious Adverse Effects

Cushing Syndrome:

• Result of chronic glucocorticoid excess (over-replacement)
• Clinical features: Central obesity, moon facies, buffalo hump, purple striae, proximal myopathy, hypertension, hyperglycemia, osteoporosis, easy bruising, psychiatric disturbances
• Diagnosis: Elevated 24-hour urinary free cortisol, failure to suppress cortisol after dexamethasone suppression test
• Management: Reduce hydrocortisone dose to lowest effective replacement level

Adrenal Suppression and Crisis:

• Chronic hydrocortisone therapy (even at replacement doses) suppresses the HPA axis
• Abrupt discontinuation or inadequate stress dosing can precipitate adrenal crisis
• Prevention: Never abruptly stop hydrocortisone; provide stress-dose coverage during illness/surgery
• Patient education: Medical alert bracelet, emergency injectable hydrocortisone

Immunosuppression and Infection Risk:

• Corticosteroids suppress cellular and humoral immunity
• Increased susceptibility to bacterial, viral, fungal, and opportunistic infections
• Infections may be mild but can be severe and fatal; risk increases with dose
• Masked infections: Corticosteroids may suppress fever and inflammatory signs, delaying diagnosis
• Opportunistic infections: Tuberculosis reactivation, Pneumocystis jirovecii pneumonia, candidiasis, aspergillosis
• Vaccine response: Live vaccines contraindicated during immunosuppressive therapy

Psychiatric Effects:

• Mood changes, irritability, anxiety, insomnia (even at replacement doses in some patients)
• Severe reactions: Mania, psychosis, severe depression (more common with pharmacologic doses)
• Risk factors: Personal or family history of psychiatric illness
• Management: Dose reduction if possible; psychiatric consultation for severe symptoms

Cardiovascular Events:

• Increased risk of myocardial infarction and stroke with long-term use
• Hypertension, fluid retention, dyslipidemia contribute to cardiovascular risk

Thromboembolic Events:

• Increased risk of deep vein thrombosis and pulmonary embolism
• Hypercoagulable state induced by corticosteroids

6.3 Pediatric-Specific Concerns

Growth Suppression:

• Chronic glucocorticoid therapy suppresses linear growth in children
• Mechanism: Direct inhibition of growth hormone secretion and IGF-1 production, suppression of growth plate chondrocyte proliferation
• Monitoring: Plot height velocity; growth deceleration may indicate over-replacement
• Risk mitigation: Use lowest effective dose; consider growth-sparing formulations (modified-release)

Bone Mineral Density:

• Children on chronic corticosteroid therapy at higher risk for osteopenia and fractures
• Ensure adequate calcium and vitamin D supplementation
• Monitor bone density with DEXA scans in high-risk patients

6.4 Under-Replacement Risks

Insufficient hydrocortisone dosing produces symptoms of adrenal insufficiency:

• Chronic fatigue, weakness, malaise
• Hypotension, orthostatic hypotension
• Hyponatremia, hyperkalemia (primary adrenal insufficiency)
• Weight loss, anorexia
• Hypoglycemia (especially in children)
• Increased risk of adrenal crisis during physiologic stress

6.5 Specific Warnings

Systemic Fungal Infections:

• Hydrocortisone is contraindicated in systemic fungal infections
• May exacerbate fungal infections and mask symptoms

Tuberculosis:

• Screen for latent tuberculosis before initiating therapy
• Reactivation of latent TB can occur with immunosuppressive doses
• Consider prophylactic antitubercular therapy in high-risk patients

Ocular Herpes Simplex:

• Corticosteroids may exacerbate ocular herpes and lead to corneal perforation

Gastrointestinal Perforation:

• Risk increased in patients with diverticulitis, peptic ulcer disease, or recent intestinal anastomosis

Kaposi's Sarcoma:

• Rare cases reported with corticosteroid use in HIV-positive patients

7. Drug Interactions

7.1 CYP3A4-Mediated Interactions

CYP3A4 Inducers (Decrease Hydrocortisone Levels):

Drugs that induce CYP3A4 increase hydrocortisone metabolism, potentially leading to inadequate cortisol replacement and adrenal insufficiency symptoms:

• Anticonvulsants: Phenytoin, carbamazepine, phenobarbital, primidone
• Antimicrobials: Rifampin, rifabutin
• Herbal supplements: St. John's wort (Hypericum perforatum)
• Others: Efavirenz, nevirapine

Clinical management:

• Monitor for signs of adrenal insufficiency (fatigue, hypotension, weight loss)
• Consider increasing hydrocortisone dose by 50-100% during concurrent use
• Monitor clinical response and adjust dose accordingly
• When inducer discontinued, reduce hydrocortisone to baseline dose to avoid over-replacement

CYP3A4 Inhibitors (Increase Hydrocortisone Levels):

Drugs that inhibit CYP3A4 decrease hydrocortisone metabolism, potentially causing glucocorticoid excess:

• Antifungals: Ketoconazole, itraconazole, fluconazole, posaconazole, voriconazole
• Macrolide antibiotics: Clarithromycin, erythromycin
• Antiretrovirals: Ritonavir, cobicistat, indinavir, nelfinavir
• Calcium channel blockers: Diltiazem, verapamil
• Others: Grapefruit juice, aprepitant, cimetidine

Clinical management:

• Monitor for signs of glucocorticoid excess (hyperglycemia, hypertension, weight gain, mood changes)
• Consider reducing hydrocortisone dose if prolonged co-administration required
• Avoid grapefruit juice consumption with hydrocortisone

7.2 Anticoagulant Interactions

Warfarin:

• Hydrocortisone produces variable effects on anticoagulation
• May increase anticoagulant effect by reducing vitamin K-dependent clotting factor synthesis
• May decrease anticoagulant effect via unknown mechanisms
• Clinical management: Monitor INR closely when initiating, adjusting, or discontinuing hydrocortisone; adjust warfarin dose as needed

Direct Oral Anticoagulants (DOACs):

• Limited data on interactions with apixaban, rivaroxaban, dabigatran, edoxaban
• Theoretical increased bleeding risk due to GI mucosal effects and antiplatelet effects

7.3 NSAID and Antiplatelet Drug Interactions

NSAIDs (Ibuprofen, Naproxen, Aspirin, Others):

• Concurrent use with corticosteroids increases GI bleeding risk approximately 4-fold
• Additive GI mucosal irritation
• Clinical management:
  • Avoid concurrent use if possible
  • If necessary, use lowest effective NSAID dose for shortest duration
  • Consider proton pump inhibitor (PPI) prophylaxis during concurrent therapy
  • Monitor for signs of GI bleeding (melena, hematemesis, anemia)

Aspirin:

• Corticosteroids may reduce serum salicylate levels
• Discontinuation of corticosteroids may lead to salicylate toxicity
• Monitor salicylate levels in patients on high-dose aspirin

7.4 Antidiabetic Drug Interactions

Insulin and Oral Hypoglycemics:

• Hydrocortisone antagonizes insulin action and increases blood glucose
• May require increased antidiabetic medication doses
• Clinical management:
  • Monitor blood glucose closely when initiating or adjusting hydrocortisone
  • Increase insulin or oral hypoglycemic doses as needed to maintain glycemic control
  • When hydrocortisone dose reduced or discontinued, reduce antidiabetic medications to prevent hypoglycemia

Affected Medications:

• Insulin (all formulations)
• Metformin
• Sulfonylureas (glipizide, glyburide, glimepiride)
• DPP-4 inhibitors (sitagliptin, linagliptin)
• GLP-1 agonists (liraglutide, semaglutide)
• SGLT2 inhibitors (empagliflozin, dapagliflozin)

7.5 Antihypertensive Drug Interactions

General Effect:

• Hydrocortisone may reduce effectiveness of antihypertensive medications due to sodium retention and increased vascular reactivity

Affected Drug Classes:

• ACE inhibitors (lisinopril, enalapril)
• Angiotensin receptor blockers (losartan, valsartan)
• Beta-blockers (metoprolol, atenolol)
• Calcium channel blockers (amlodipine, nifedipine)
• Diuretics (paradoxical interaction; see below)

Clinical management:

• Monitor blood pressure regularly
• Adjust antihypertensive doses as needed
• Optimize hydrocortisone dose to minimize mineralocorticoid effects

7.6 Diuretic Interactions

Potassium-Depleting Diuretics:

• Loop diuretics: Furosemide, bumetanide, torsemide
• Thiazide diuretics: Hydrochlorothiazide, chlorthalidone

Interaction mechanism:

• Both hydrocortisone (mineralocorticoid effect) and diuretics promote potassium excretion
• Additive hypokalemia risk

Clinical management:

• Monitor serum potassium regularly
• Consider potassium supplementation or potassium-sparing diuretic (amiloride, triamterene)
• Severe hypokalemia may cause cardiac arrhythmias, muscle weakness, rhabdomyolysis

7.7 Anticholinesterase Interactions

Myasthenia Gravis Medications:

• Pyridostigmine, neostigmine

Interaction:

• Corticosteroids may reduce effectiveness of anticholinesterase agents in myasthenia gravis
• Paradoxically, corticosteroids are also used to treat myasthenia gravis

Clinical management:

• Monitor muscle strength
• Adjust anticholinesterase dose as needed

7.8 Immunosuppressant Interactions

Cyclosporine, Tacrolimus:

• Hydrocortisone (as CYP3A4 inducer at high doses) may reduce cyclosporine/tacrolimus levels
• Concurrent use increases immunosuppression and infection risk
• Monitor immunosuppressant levels and adjust doses

7.9 Vaccine Interactions

Live Vaccines:

• Contraindicated during immunosuppressive-dose corticosteroid therapy
• Risk of vaccine-strain infection in immunocompromised patients
• Examples: MMR, varicella, yellow fever, oral polio (not used in US), live attenuated influenza (nasal spray)

Inactivated Vaccines:

• Safe to administer but may have reduced immunogenicity
• Examples: Influenza (injectable), pneumococcal, hepatitis A/B, COVID-19 (mRNA, viral vector)
• Consider giving vaccines during periods of lower immunosuppression if possible

Timing Recommendations:

• Hold live vaccines until at least 1 month after discontinuation of immunosuppressive doses
• Replacement-dose hydrocortisone (15-25 mg daily) generally does not preclude live vaccines

7.10 Other Significant Interactions

Cholestyramine:

• May reduce absorption of hydrocortisone
• Separate administration by at least 4 hours

Estrogen/Oral Contraceptives:

• Increase cortisol-binding globulin (CBG), reducing free cortisol
• May necessitate hydrocortisone dose increase
• Effect usually minimal at replacement doses

Thyroid Hormone:

• Thyroid hormone replacement increases cortisol clearance
• Initiating levothyroxine in patient with undiagnosed adrenal insufficiency can precipitate adrenal crisis
• Always assess and treat adrenal insufficiency before initiating thyroid hormone replacement in hypopituitarism

Ephedrine:

• Increases hydrocortisone clearance
• May require dose adjustment

Amphotericin B:

• Additive hypokalemia risk
• Monitor potassium closely

8. Contraindications and Warnings

8.1 Absolute Contraindications

Systemic Fungal Infections:

• Hydrocortisone is contraindicated in patients with systemic fungal infections unless required as life-saving therapy for adrenal crisis
• Corticosteroids suppress cell-mediated immunity critical for fungal defense
• Examples: Disseminated candidiasis, cryptococcosis, aspergillosis, coccidioidomycosis, histoplasmosis
• Topical fungal infections (tinea pedis, tinea corporis, tinea cruris) are NOT contraindications to systemic hydrocortisone for replacement therapy

Hypersensitivity:

• Known hypersensitivity to hydrocortisone or formulation components
• Anaphylactic reactions rare but reported

Live Vaccine Administration:

• Live vaccines contraindicated during immunosuppressive-dose corticosteroid therapy
• Replacement doses (15-25 mg daily) generally do not preclude live vaccine administration

8.2 Relative Contraindications and Precautions

Active or Latent Tuberculosis:

• Screen for latent TB before initiating prolonged corticosteroid therapy
• Reactivation risk with immunosuppressive doses
• Consider isoniazid prophylaxis in high-risk patients (positive tuberculin test, history of inadequately treated TB, recent TB exposure)

Herpes Simplex Keratitis (Ocular Herpes):

• Corticosteroids may exacerbate ocular herpes simplex and cause corneal perforation
• Ophthalmologic consultation recommended

Strongyloidiasis (Threadworm Infection):

• Corticosteroids may cause strongyloides hyperinfection and dissemination
• Screen for strongyloides in patients with appropriate epidemiologic risk (endemic area residence/travel)
• Treat latent infection before initiating corticosteroids if possible

Peptic Ulcer Disease:

• Active or history of peptic ulcer disease
• Increased risk of GI bleeding and perforation with corticosteroids
• Consider PPI prophylaxis
• Monitor for signs of GI bleeding

Diverticulitis:

• Risk of intestinal perforation
• Use with caution; avoid if possible during acute diverticulitis

Recent Intestinal Anastomosis:

• Risk of anastomotic dehiscence (breakdown)
• Avoid corticosteroids in immediate postoperative period if possible

Myocardial Infarction (Recent):

• Corticosteroids associated with myocardial rupture in some case reports
• Use with caution in acute MI setting

Congestive Heart Failure:

• Sodium and fluid retention may exacerbate heart failure
• Monitor volume status closely
• Consider reducing fludrocortisone dose or using corticosteroid with less mineralocorticoid activity

Hypertension:

• Hydrocortisone may worsen blood pressure control
• Monitor BP; adjust antihypertensive medications as needed

Diabetes Mellitus:

• Hydrocortisone worsens glycemic control
• Monitor blood glucose closely
• Adjust antidiabetic medications as needed
• Not a contraindication; patients with diabetes and adrenal insufficiency require hydrocortisone replacement

Osteoporosis:

• Corticosteroids accelerate bone loss
• Baseline DEXA scan recommended
• Ensure adequate calcium (1200-1500 mg daily) and vitamin D (800-1000 IU daily)
• Consider bisphosphonate therapy for patients at high fracture risk

Glaucoma:

• Corticosteroids may increase intraocular pressure
• Ophthalmologic monitoring recommended for patients with glaucoma or at risk

Psychiatric Disorders:

• Personal or family history of severe psychiatric illness
• Monitor mood; consider psychiatric consultation if severe mood changes occur
• Not an absolute contraindication to replacement therapy but requires close monitoring

Hypothyroidism:

• Initiating thyroid hormone replacement in patient with undiagnosed adrenal insufficiency can precipitate adrenal crisis
• Always evaluate and treat adrenal insufficiency before starting levothyroxine in hypopituitarism

8.3 Special Warnings

Immunosuppression and Infection Risk:

• Corticosteroids weaken the immune system, making it easier to get an infection or worsen an existing infection
• Corticosteroid-associated infections can be mild but can be severe and fatal
• Patients should avoid exposure to chickenpox and measles; seek immediate medical attention if exposed
• Report signs of infection (fever, persistent sore throat, cough) promptly

HPA Axis Suppression:

• Chronic hydrocortisone therapy (even replacement doses) suppresses the HPA axis
• Patients cannot mount endogenous cortisol response to stress
• Critical patient education: Carry medical alert identification, emergency injectable hydrocortisone, written stress-dosing instructions

Kaposi's Sarcoma:

• Rare reports of Kaposi's sarcoma in patients receiving corticosteroids
• Mechanism unclear; may relate to immunosuppression in HIV-positive patients

Acute Myopathy:

• High-dose corticosteroids (pharmacologic doses, not typical replacement doses) can cause acute myopathy
• Particularly in patients receiving neuromuscular blocking agents (e.g., ICU setting)
• Manifests as severe proximal muscle weakness, elevated creatine kinase
• Usually reversible with discontinuation

Pheochromocytoma Crisis:

• Corticosteroids may precipitate hypertensive crisis in patients with pheochromocytoma
• Screen for pheochromocytoma if clinical suspicion

Pediatric Growth Suppression:

• Prolonged use may suppress growth in children
• Monitor height velocity
• Use lowest effective dose
• Not a contraindication to necessary replacement therapy but requires monitoring

Pregnancy and Lactation Warnings:

• See Section 9.1 for detailed discussion
• Hydrocortisone readily crosses the placenta; animal studies show teratogenicity
• Adrenal insufficiency must be treated during pregnancy; untreated adrenal insufficiency poses greater risk than replacement therapy
• Compatible with breastfeeding at replacement doses

9. Special Populations

9.1 Pregnancy and Lactation

Pregnancy Safety:

FDA Pregnancy Category (Historical):

• Former FDA pregnancy category: C (systemic use)
• Note: FDA removed pregnancy letter categories (A, B, C, D, X) in 2015 under the Pregnancy and Lactation Labeling Rule (PLLR)

Placental Transfer and Fetal Exposure:

• Hydrocortisone readily crosses the placenta
• Placental 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) converts maternal cortisol to inactive cortisone, providing partial fetal protection
• Despite placental inactivation, high maternal doses can expose the fetus to significant glucocorticoid levels

Animal Teratogenicity Data:

• Animal studies show increased incidence of cleft palate with corticosteroid exposure
• Relevance to humans has been questioned; human epidemiologic data show minimal risk at physiologic replacement doses

Human Pregnancy Data:

• Adrenal insufficiency in pregnancy: Untreated maternal adrenal insufficiency poses significant risks including maternal adrenal crisis, miscarriage, preterm labor, fetal growth restriction, and maternal/fetal death
• Replacement therapy: Usual hydrocortisone replacement doses (15-25 mg daily) should be continued throughout pregnancy
• Risk-benefit: Benefits of treating maternal adrenal insufficiency far outweigh theoretical fetal risks from physiologic hydrocortisone replacement

Pregnancy Management:

• Continue usual hydrocortisone replacement dose throughout pregnancy
• Some experts recommend increasing dose by 50% in third trimester due to increased cortisol-binding globulin (CBG) levels, though this remains controversial
• Labor and delivery stress dosing: 100 mg IV hydrocortisone at onset of active labor, then 50 mg IV every 6 hours until delivery
• Cesarean section: Same stress-dose protocol as major surgery (100 mg IV at induction, then 50 mg IV every 6-8 hours for 24-48 hours)

Neonatal Considerations:

• Neonates born to mothers on chronic high-dose corticosteroids (pharmacologic doses, not typical replacement) should be monitored for adrenal suppression
• Replacement-dose hydrocortisone in mother unlikely to cause neonatal adrenal suppression

Lactation/Breastfeeding:

According to the LactMed database (updated November 15, 2025):

Hydrocortisone in Breast Milk:

• Hydrocortisone (cortisol) is a normal component of breast milk
• Exogenous hydrocortisone in pharmacologic amounts has not been extensively studied in milk
• Replacement doses considered compatible: Single doses, local use, and maternal doses up to 160 mg per day are generally compatible with breastfeeding

Effects on Breastfed Infants:

• Maternal use of hydrocortisone as enema or local injections (e.g., for tendinitis) would not be expected to cause adverse effects in breastfed infants
• No adverse effects reported in nursing infants with maternal replacement therapy

Effects on Lactation:

• Medium to large doses of corticosteroids given systemically or injected into joints or breast have been reported to cause temporary reduction of lactation
• Replacement doses (15-25 mg daily) unlikely to affect milk production

Recommendations:

• Hydrocortisone replacement therapy compatible with breastfeeding
• Monitor infant for adequate weight gain and growth
• If high-dose therapy required (>40 mg daily), consider monitoring infant for signs of glucocorticoid exposure (poor growth, immunosuppression)

9.2 Pediatric Patients

Dosing Considerations:

• Standard replacement: 8 mg/m²/day divided into 2-3 doses
• Infants and young children may require higher doses per body surface area (10-15 mg/m²/day) due to increased metabolic clearance
• Congenital adrenal hyperplasia: 10-20 mg/m²/day to suppress androgen production

Growth Monitoring:

• Critical concern: Chronic glucocorticoid therapy suppresses linear growth
• Mechanism: Suppression of growth hormone secretion, reduced IGF-1, direct inhibition of growth plate chondrocyte proliferation
• Plot height velocity at each visit; growth deceleration indicates possible over-replacement
• Goal: Maintain growth along expected percentile curve

Dosing Strategy to Minimize Growth Suppression:

• Use lowest effective dose
• Avoid late evening doses that suppress physiologic overnight growth hormone secretion
• Consider modified-release formulations designed to minimize overnight exposure

Bone Health:

• Children on chronic corticosteroid therapy at increased risk for osteopenia and fractures
• Ensure adequate calcium and vitamin D intake
• DEXA scans for bone density monitoring in high-risk patients

Stress Dosing in Children:

• Minor illness: Double usual dose
• Moderate illness (fever, gastroenteritis): 50-100 mg/m² daily in divided doses
• Severe illness/surgery: 100 mg/m² IV bolus, then 100 mg/m²/day continuous infusion or divided q6h
• Parents should be educated on stress dosing and have injectable hydrocortisone at home

Liquid Formulations:

• KHINDIVI oral solution (5 mg/mL) FDA-approved for pediatric use
• Compounded suspensions available from specialty pharmacies
• Facilitates accurate dosing in infants and young children

9.3 Geriatric Patients

Dosing Adjustments:

• Start at lower end of dosing range (15 mg daily rather than 20-25 mg)
• Elderly patients may have reduced clearance due to decreased hepatic function
• Increased sensitivity to corticosteroid adverse effects

Increased Risk of Adverse Effects:

Osteoporosis and Fractures:

• Elderly already at higher baseline fracture risk
• Corticosteroids accelerate bone loss
• Baseline DEXA scan recommended
• Calcium 1200-1500 mg daily and vitamin D 800-1000 IU daily
• Consider bisphosphonate (alendronate, risedronate) or denosumab for osteoporosis prevention

Hyperglycemia and Diabetes:

• Age-related insulin resistance compounded by glucocorticoid effects
• Higher risk of new-onset diabetes
• Monitor fasting glucose and HbA1c regularly

Hypertension:

• Mineralocorticoid effects (sodium retention) may worsen age-related hypertension
• Monitor blood pressure closely
• Adjust antihypertensive medications as needed

Cognitive Effects:

• Elderly more susceptible to corticosteroid-induced cognitive impairment and delirium
• Monitor mental status, especially during stress-dose therapy

Falls Risk:

• Corticosteroid myopathy increases fall risk in elderly
• Osteoporosis + falls = high fracture risk
• Physical therapy, home safety evaluation recommended

Polypharmacy Interactions:

• Elderly typically on multiple medications, increasing drug interaction risk
• Review medication list for CYP3A4 inducers/inhibitors, anticoagulants, NSAIDs, antidiabetic agents
• Adjust doses as needed

9.4 Renal Impairment

Pharmacokinetics:

• Hydrocortisone clearance not significantly affected by renal dysfunction
• Metabolites (inactive) may accumulate but clinically insignificant

Dosing:

• No routine dose adjustment required for renal impairment (CKD stages 1-5, including dialysis)
• Continue usual replacement dose based on clinical response

Monitoring:

• Monitor fluid and electrolyte balance closely
• Mineralocorticoid effects (sodium retention) may worsen fluid overload in advanced CKD
• Patients on dialysis may require fludrocortisone dose adjustment based on blood pressure and interdialytic weight gain

9.5 Hepatic Impairment

Pharmacokinetics:

• Severe liver disease reduces hydrocortisone metabolism
• Decreased clearance may lead to glucocorticoid accumulation

Dosing:

• Mild-to-moderate hepatic impairment: No adjustment required; monitor clinical response
• Severe hepatic impairment (Child-Pugh C): Consider dose reduction
• Monitor for signs of glucocorticoid excess (hyperglycemia, hypertension, fluid retention, mood changes)

Protein Binding Alterations:

• Liver disease reduces cortisol-binding globulin (CBG) synthesis
• Lower CBG increases free (unbound) cortisol fraction, enhancing biologic effects
• May necessitate lower total dose to achieve equivalent free cortisol levels

Clinical Monitoring:

• Assess clinical symptoms of adrenal insufficiency vs. excess
• Consider measuring free cortisol or salivary cortisol (not affected by CBG) rather than total serum cortisol

9.6 Obesity

Dosing Strategy:

• Dose based on ideal body weight or body surface area (mg/m²), not total body weight
• Dosing based on total weight in obese patients may lead to over-replacement and Cushingoid features

Metabolic Considerations:

• Obesity associated with increased 11β-HSD1 activity (converts inactive cortisone to active cortisol)
• May result in tissue-specific cortisol excess despite normal serum cortisol
• Use clinical symptoms to guide dosing rather than relying solely on biochemical measures

Cortisol Binding Globulin:

• Obesity generally does not significantly affect CBG levels
• Standard total serum cortisol measurements remain valid

9.7 Diabetes Mellitus

Glycemic Impact:

• Hydrocortisone antagonizes insulin action and stimulates gluconeogenesis
• Worsens glycemic control; may unmask latent diabetes

Management:

• Not a contraindication: Patients with diabetes and adrenal insufficiency require hydrocortisone replacement
• Monitor blood glucose closely when initiating or adjusting hydrocortisone
• Increase antidiabetic medication doses as needed
• Target HbA1c <7% if possible

Stress Dosing:

• During illness requiring stress-dose hydrocortisone, expect significant hyperglycemia
• May require temporary insulin therapy even in patients usually controlled with oral agents
• Monitor blood glucose every 4-6 hours during stress-dose therapy

9.8 Cardiovascular Disease

Hypertension:

• Mineralocorticoid effects may worsen blood pressure control
• Monitor BP regularly; adjust antihypertensive medications
• Consider reducing fludrocortisone dose if hypertension worsens

Congestive Heart Failure:

• Sodium and fluid retention may precipitate or worsen heart failure
• Use lowest effective hydrocortisone dose
• Consider diuretic therapy or reduce fludrocortisone dose
• Monitor daily weights, edema, dyspnea

Coronary Artery Disease:

• Hydrocortisone may worsen dyslipidemia and hyperglycemia, increasing cardiovascular risk
• Aggressive lipid and glucose management recommended
• Not a contraindication to necessary replacement therapy

Anticoagulation:

• Many cardiac patients on warfarin or DOACs
• Monitor INR closely; adjust warfarin as needed (see Section 7.2)

9.9 Immunocompromised Patients

HIV/AIDS:

• Adrenal insufficiency relatively common in advanced HIV
• Hydrocortisone replacement therapy essential
• Increased risk of opportunistic infections with immunosuppressive doses
• Monitor for tuberculosis reactivation, fungal infections, cytomegalovirus
• Ensure antiretroviral therapy optimized

Organ Transplant Recipients:

• Already on immunosuppressive therapy (tacrolimus, cyclosporine, mycophenolate)
• Adding hydrocortisone increases infection risk
• CYP3A4 interactions may alter calcineurin inhibitor levels (see Section 7.8)
• Close monitoring required

Malignancy/Chemotherapy:

• Chemotherapy-induced adrenal insufficiency may occur (especially with checkpoint inhibitors)
• Hydrocortisone replacement needed despite increased infection risk
• Prophylactic antimicrobials (e.g., trimethoprim-sulfamethoxazole for PCP prophylaxis) may be indicated

10. Monitoring Requirements

10.1 Clinical Monitoring

Baseline Assessment:

• Complete history and physical examination
• Document signs/symptoms of adrenal insufficiency (fatigue, hypotension, hyperpigmentation, weight loss)
• Assess for comorbidities (diabetes, hypertension, osteoporosis, psychiatric disorders)
• Medication review for drug interactions

Ongoing Clinical Monitoring:

At Each Visit (Every 3-6 Months):

• Symptoms: Energy level, orthostatic symptoms, appetite, weight changes
• Blood pressure: Assess for hypotension (under-replacement) or hypertension (over-replacement or excess fludrocortisone)
• Weight: Weight loss suggests under-replacement; weight gain (especially central adiposity) suggests over-replacement
• Hyperpigmentation: In primary adrenal insufficiency, persistent or worsening hyperpigmentation indicates elevated ACTH from under-replacement
• Edema: Suggests over-replacement or excess fludrocortisone

Signs of Under-Replacement:

• Persistent fatigue despite adequate sleep
• Orthostatic hypotension, dizziness
• Weight loss, poor appetite
• Hyperpigmentation (primary AI)
• Salt craving (primary AI)
• Recurrent hypoglycemia (children)

Signs of Over-Replacement:

• Weight gain (central obesity, moon facies, buffalo hump)
• Hypertension
• Hyperglycemia
• Insomnia, mood changes
• Easy bruising, skin thinning
• Proximal muscle weakness

10.2 Laboratory Monitoring

Baseline Laboratory Tests:

• Morning cortisol: Establish baseline if diagnosis uncertain (8 AM cortisol <3 mcg/dL confirms adrenal insufficiency; >15 mcg/dL excludes it)
• ACTH: Distinguishes primary (elevated ACTH) from secondary/tertiary (low-normal ACTH) adrenal insufficiency
• Electrolytes: Hyponatremia and hyperkalemia in primary AI
• Glucose: Baseline fasting glucose and HbA1c
• Complete blood count: Mild anemia and eosinophilia may occur in adrenal insufficiency
• Renin and aldosterone: In primary AI, elevated renin and low aldosterone; guides fludrocortisone dosing

Monitoring During Hydrocortisone Therapy:

Not Routinely Recommended:

• Serial serum cortisol measurements are NOT useful for monitoring adequacy of hydrocortisone replacement
• Cortisol levels fluctuate throughout the day and after each dose
• Timing of blood draw relative to dose makes interpretation unreliable
• Clinical assessment is superior to biochemical monitoring

Electrolytes (Primary Adrenal Insufficiency):

• Check sodium and potassium every 3-6 months
• Persistent hyponatremia or hyperkalemia suggests inadequate fludrocortisone or under-replacement
• Hypokalemia suggests fludrocortisone over-replacement

Renin (Primary Adrenal Insufficiency):

• Plasma renin activity (PRA) or direct renin concentration
• Target: Upper half of normal range (indicates adequate mineralocorticoid replacement without excess)
• Check every 6-12 months or when adjusting fludrocortisone dose
• Elevated renin: Increase fludrocortisone dose
• Suppressed renin: Decrease fludrocortisone dose

Glucose Monitoring:

• Fasting glucose and HbA1c every 6-12 months
• More frequent in patients with diabetes or prediabetes
• Target HbA1c <7% in most patients

Lipid Panel:

• Baseline and annually
• Hydrocortisone may worsen dyslipidemia
• Treat per standard cardiovascular risk guidelines

Bone Density (DEXA Scan):

• Baseline DEXA scan in patients at risk for osteoporosis:
  • Postmenopausal women
  • Men >50 years
  • History of fragility fracture
  • Long-term corticosteroid use (even at replacement doses)
• Repeat every 1-2 years if osteopenia or osteoporosis present
• Less frequent if normal bone density (every 3-5 years)

Additional Monitoring in Specific Populations:

Children:

• Height and weight at every visit; plot on growth charts
• Bone age X-ray annually if concerns about growth
• 17-hydroxyprogesterone and androstenedione in CAH patients (every 3-6 months)

Pregnant Women:

• Electrolytes monthly (primary AI)
• Blood pressure at each prenatal visit
• Ensure stress-dose coverage plan for labor/delivery documented in chart

10.3 Patient Education and Self-Monitoring

Critical Patient Education Components:

Stress Dosing:

• Written instructions for doubling/tripling dose during minor illness
• When to seek emergency care (vomiting preventing oral intake, severe illness)
• How to self-administer or have family member administer emergency IM/IV hydrocortisone

Medical Alert Identification:

• Medical alert bracelet or necklace stating "Adrenal Insufficiency - Requires Stress-Dose Corticosteroids"
• Include patient name, diagnosis, home medications, emergency contact

Emergency Kit:

• Injectable hydrocortisone (Solu-Cortef 100 mg Act-O-Vial)
• Instructions for IM administration
• Glucagon kit (for hypoglycemia, especially children)
• Written stress-dose instructions

Medication Adherence:

• Never skip doses
• Never abruptly discontinue hydrocortisone
• Take largest dose upon waking to mimic circadian rhythm

Signs of Adrenal Crisis:

• Severe weakness, confusion, loss of consciousness
• Severe nausea/vomiting preventing oral intake
• Severe hypotension
• Severe abdominal or back pain
• Action: Administer emergency injectable hydrocortisone AND call 911

Sick Day Rules:

• Fever, vomiting, diarrhea, or any illness → increase dose
• Minor illness: Double or triple usual daily dose
• Vomiting: Go to emergency room for IV hydrocortisone

11. Cost and Accessibility

11.1 Medication Costs (2024)

Generic Hydrocortisone Tablets:

• 90-day supply (typical replacement dose): $12-77
• 30-day supply: $4-26
• Cost per day: $0.13-$0.86 (at usual 15-25 mg daily dose)

Brand-Name Cortef®:

• 90 tablets (30-day supply at typical 20 mg daily dose): $212-300
• 100 tablets: $235-330
• Approximately 10-15 times more expensive than generic
• No therapeutic advantage over generic; brand use rarely justified

KHINDIVI® Oral Solution:

• FDA-approved oral solution (5 mg/mL concentration)
• Approved in 2024 as first FDA-approved oral solution for adrenal insufficiency
• Cost: Not yet widely available; pricing not established at time of publication
• Intended primarily for pediatric use where precise dosing critical

Modified-Release Formulations:

• Plenadren® (dual-release hydrocortisone): Not widely available in United States; approved in Europe
• Estimated cost: $200-400 per month (significantly more expensive than immediate-release generic)
• Insurance coverage variable

Injectable Hydrocortisone (Solu-Cortef®):

• 100 mg Act-O-Vial (for emergency use): $15-35 per vial
• Patients should have 2-3 vials at home for emergencies
• Usually covered by insurance with prescription

GoodRx and Discount Programs:

• GoodRx coupons can reduce generic hydrocortisone cost to $21-44 for 90-day supply
• SingleCare, Blink Health, and other discount cards offer similar savings
• Particularly useful for uninsured or high-deductible plans

11.2 Insurance Coverage

Medicare:

• Generic hydrocortisone tablets covered under Part D
• Typical copay: $0-10 per month (Tier 1 generic)
• Injectable formulations covered under Part B (if administered in medical setting) or Part D (patient-administered at home)

Commercial Insurance:

• Generic hydrocortisone almost universally covered
• Tier 1 (preferred generic) placement on most formularies
• Typical copay: $5-15 per month
• Prior authorization rarely required for standard formulations

Medicaid:

• Covered in all states as essential medication
• Copays typically $0-3 per prescription

Veterans Affairs (VA):

• Covered on VA National Formulary
• Available at no cost to eligible veterans

Prior Authorization:

• Immediate-release generic tablets: Rarely requires prior authorization
• Modified-release formulations (if available): May require prior authorization demonstrating medical necessity
• Injectable formulations for home use: May require documentation of adrenal insufficiency diagnosis

11.3 Generic vs. Brand Considerations

Generic Availability:

• Multiple generic manufacturers produce hydrocortisone tablets
• FDA-approved generic formulations are bioequivalent to brand
• Generic-to-generic switching generally safe and well-tolerated

Brand-Name Cortef®:

• Historical brand, widely used before generic availability
• No evidence of superior efficacy or safety compared to generic
• Significantly higher cost not justified in most patients
• Some patients report subjective preference for brand, but controlled studies show no difference

Compounded Formulations:

• Some patients use compounded hydrocortisone from specialty pharmacies
• May be necessary for:
  • Liquid formulations (pediatric dosing) where FDA-approved oral solution not available or affordable
  • Custom doses not available as commercial tablets (e.g., 7.5 mg, 12.5 mg)
• Cost: Variable; often more expensive than commercial tablets but less than brand
• Quality concerns: Compounded medications not FDA-approved; quality depends on pharmacy
• FDA-approved products preferred when available

11.4 Accessibility and Availability

Pharmacy Availability:

• Generic hydrocortisone tablets widely stocked at all major pharmacy chains (CVS, Walgreens, Walmart, Rite Aid, etc.)
• Independent pharmacies typically stock or can order within 24 hours
• Injectable formulations (Solu-Cortef) may require special order at some pharmacies; call ahead

Online Pharmacies:

• Generic hydrocortisone available from reputable online pharmacies (Express Scripts, OptumRx, Amazon Pharmacy)
• 90-day supplies often available at lower cost than 30-day retail
• Verify pharmacy is licensed and VIPPS-accredited (Verified Internet Pharmacy Practice Sites)

International Availability:

• Hydrocortisone is widely available globally as essential medication on WHO Model List of Essential Medicines
• Generic versions available in most countries
• Travelers should carry sufficient supply plus extra for stress dosing
• Carry letter from physician documenting diagnosis and prescription

Shortage Risk:

• Hydrocortisone tablets generally not subject to shortages due to multiple manufacturers
• Injectable formulations occasionally experience temporary shortages
• FDA Drug Shortages Database (www.accessdata.fda.gov/scripts/drugshortages) provides current information

11.5 Patient Assistance Programs

Manufacturer Programs:

• Pfizer Patient Assistance Program (for Cortef brand if prescribed): Income-based eligibility
• Apply through: www.pfizerpatientassistance.com or call 1-866-706-2400

Non-Profit Assistance:

• NeedyMeds: Database of patient assistance programs; www.needymeds.org
• RxAssist: Comprehensive database of assistance programs; www.rxassist.org
• Partnership for Prescription Assistance: www.pparx.org

Manufacturer Copay Cards:

• Generally not available for generic medications
• If brand Cortef prescribed, copay card may be available from Pfizer

11.6 Cost-Effectiveness Considerations

Cost per Day (Generic):

• $0.13-$0.86 per day for hydrocortisone replacement therapy
• Extremely cost-effective medication for life-sustaining therapy

Total Annual Cost:

• Hydrocortisone tablets: $50-300 per year
• Laboratory monitoring (annual): $100-300
• Endocrinology visits (2-4 per year): $400-1,200
• Injectable hydrocortisone for emergencies: $30-100 (one-time/annual)
• Total estimated annual cost: $580-1,900

Cost of Untreated Adrenal Insufficiency:

• Adrenal crisis hospitalization: $10,000-50,000 per episode
• ICU admission for severe adrenal crisis: $50,000-100,000+
• Preventable with proper hydrocortisone replacement and patient education
• Cost-effectiveness: Hydrocortisone therapy is highly cost-effective, preventing costly hospitalizations

Quality of Life:

• Untreated or under-treated adrenal insufficiency: Severe fatigue, inability to work, reduced quality of life
• Proper replacement therapy: Restoration of normal quality of life, ability to work and function
• Priceless benefit at very low medication cost

12. Clinical Evidence and Efficacy

12.1 Evidence for Replacement Therapy Efficacy

Historical Perspective:

• Before hydrocortisone availability (pre-1950s), adrenal insufficiency (Addison's disease) was universally fatal
• Introduction of cortisone (1949) and hydrocortisone (early 1950s) transformed adrenal insufficiency from a fatal disease to a manageable chronic condition
• Dramatic efficacy established through decades of clinical experience rather than randomized controlled trials (RCTs would be unethical given life-saving nature)

Mortality Data:

• Untreated primary adrenal insufficiency: Near 100% mortality
• Treated adrenal insufficiency with hydrocortisone replacement: Mortality not normalized but significantly improved; quality of life remains poor with traditional approaches
• Standardized mortality ratio (SMR) for treated adrenal insufficiency: Approximately 2.0-2.5 (two-fold increased mortality compared to general population)
• Causes of excess mortality: Adrenal crises, cardiovascular disease, infections
• Improvement strategies: Patient education on stress dosing, medical alert identification, emergency injectable hydrocortisone access

Quality of Life Studies:

• Quality of life remains poor with traditional hydrocortisone approaches despite adequate biochemical replacement
• Patients report persistent fatigue, reduced physical functioning, and impaired emotional well-being compared to healthy controls
• Contributing factors: Non-physiologic cortisol rhythm from immediate-release formulations, inability to mimic stress-induced cortisol surges, concurrent mineralocorticoid and other hormone deficiencies in some patients

12.2 Optimal Dosing Studies

Current Guideline Recommendations:

• Endocrine Society Guidelines recommend 15-25 mg daily with midpoint of 20 mg
• Based on estimated physiologic cortisol production of approximately 8-10 mg/m²/day (15-20 mg daily in average adult)

Real-World Dosing Practices:

• Empirically determined mean daily dose in clinical practice: 13.9 ± 6 mg, significantly lower than guideline midpoint of 20 mg
• Suggests that guideline recommendations may overestimate replacement needs in many patients
• Implication: Individualize dosing based on clinical response rather than rigidly adhering to population-based recommendations

Higher vs. Lower Dose Comparisons:

• Studies comparing different hydrocortisone doses (e.g., 15 mg vs. 25 mg daily) show:
  • Higher doses associated with more weight gain, hyperglycemia, and Cushingoid features
  • Lower doses may result in persistent fatigue and hypotension in some patients
  • Conclusion: Use lowest dose that adequately controls symptoms and maintains normal blood pressure

12.3 Modified-Release Hydrocortisone Formulations

Rationale for Development:

• Conventional immediate-release hydrocortisone given 2-3 times daily fails to replicate physiologic circadian cortisol rhythm
• Overnight cortisol nadir too low; daytime peaks too high or poorly timed
• Hypothesis: Better cortisol rhythm replication improves metabolic outcomes and quality of life

Plenadren® (Dual-Release Hydrocortisone):

Formulation:

• Once-daily tablet with immediate-release outer layer and delayed-release core
• Achieves cortisol peak 1-2 hours after morning administration, followed by second peak 6-8 hours later

Clinical Evidence:

• Crossover study of 64 individuals with Addison's disease: 12 weeks of Plenadren therapy resulted in modest improvements in blood pressure and weight reduction
• Long-term safety study: Prospective, open-label, multicenter, 5-year extension study with 71 adult patients showed sustained safety
• Quality of life improvements modest and inconsistent across studies

Limitations:

• Bioavailability approximately 20% lower than conventional hydrocortisone; requires dose conversion
• Significantly more expensive than generic immediate-release
• Limited availability in United States (approved in Europe)

Chronocort® (Delayed- and Sustained-Release):

• Designed for bedtime administration to replicate overnight cortisol rise
• Under investigation; not yet FDA-approved in United States
• Early studies show promise for metabolic improvements

12.4 DREAM Trial (Modified-Release vs. Standard Therapy)

Study Design:

• DREAM Trial: First non-sponsored, randomised controlled trial investigating once-daily, modified-release hydrocortisone versus standard therapy on metabolism
• 89 patients with adrenal insufficiency randomly assigned to:
  • Standard treatment group (n=43): Conventional immediate-release hydrocortisone 2-3 times daily
  • Switch treatment group (n=46): Once-daily modified-release hydrocortisone

Primary Outcomes:

• Evaluated effects on metabolism and innate immunity
• Results showed modest metabolic benefits with modified-release formulation
• No dramatic quality of life improvement

Interpretation:

• Modified-release formulations offer incremental benefits over conventional therapy
• Benefits may not justify significantly higher cost for all patients
• Consider in patients with difficult-to-control symptoms, metabolic complications, or preference for once-daily dosing

12.5 Continuous Subcutaneous Hydrocortisone Infusion (CSHI)

Rationale:

• CSHI via insulin pump allows adjustable glucocorticoid delivery and can mimic more physiologic cortisol pattern
• Programmable basal rates: Higher rates in early morning, lower at night

Clinical Experience:

• Practical experience in 33 subjects shows feasibility and tolerability
• Reserved for patients with:
  • Frequent adrenal crises despite optimal oral therapy
  • Severe malabsorption (inflammatory bowel disease, short gut syndrome)
  • Persistent symptoms despite dose optimization

Limitations:

• Requires insulin pump (expense, training, infusion site management)
• Risk of pump malfunction or infusion site failure leading to adrenal crisis
• Not widely adopted; limited long-term data

12.6 Stress Dosing Evidence

Physiologic Rationale:

• Healthy individuals increase cortisol secretion 5-10 fold during stress (illness, surgery, trauma)
• Patients with adrenal insufficiency cannot mount endogenous response
• Inadequate stress dosing → adrenal crisis (hypotension, shock, potentially fatal)

Stress Dosing Protocols:

• Minor stress: Double or triple usual dose (empirically derived, not rigorously studied)
• Major surgery/severe illness: 100 mg IV bolus, then 50-100 mg every 6-8 hours or 200 mg/24 hours continuous infusion (based on estimated peak cortisol production during maximal stress)

Evidence Base:

• Stress dosing recommendations primarily based on expert consensus and physiologic principles rather than RCTs
• Observational studies show reduced adrenal crisis rates with proper patient education on stress dosing
• Over-cautious stress dosing may contribute to metabolic complications; some experts advocate for more conservative stress dosing protocols

12.7 Comparison to Alternative Corticosteroids for Replacement

Hydrocortisone vs. Prednisone:

• Comparison studies show hydrocortisone and prednisone both effective for post-adrenalectomy glucocorticoid replacement
• Hydrocortisone advantages:
  • Shorter half-life allows more physiologic dosing schedule
  • Mineralocorticoid activity (may reduce or eliminate fludrocortisone need)
  • Less HPA suppression with divided dosing
• Prednisone advantages:
  • Once-daily dosing (convenience)
  • Potentially lower cost
• Consensus: Hydrocortisone preferred for primary adrenal insufficiency; prednisone acceptable alternative in secondary/tertiary insufficiency

Hydrocortisone vs. Dexamethasone:

• Dexamethasone rarely used for chronic replacement therapy
• Extremely long half-life (36-54 hours) makes dose titration difficult
• No mineralocorticoid activity
• Use: Reserved for suppression testing or specific clinical scenarios (congenital adrenal hyperplasia with poor control on hydrocortisone)

12.8 Outcomes in Congenital Adrenal Hyperplasia (CAH)

Treatment Goals:

• Suppress ACTH-driven androgen overproduction
• Avoid glucocorticoid over-replacement (growth suppression, metabolic complications)
• Difficult balance: "Too much" vs. "too little"

Clinical Challenges:

• Optimal dosing controversial
• Higher doses (15-20 mg/m²/day) suppress androgens better but increase growth suppression risk
• Lower doses preserve growth but risk virilization in females, central precocious puberty

Long-Term Outcomes:

• Adult height often below genetic potential despite treatment
• Metabolic syndrome, obesity common in adults with CAH
• Fertility challenges, especially in females with poor control during development
• Emerging therapies: CRH antagonists, modified-release formulations designed to suppress overnight ACTH rise

13. Comparison to Alternatives

13.1 Alternative Corticosteroids for Replacement Therapy

Comparison Table:

Equivalent Doses for Replacement:

• Hydrocortisone 20 mg = Prednisone 5 mg = Dexamethasone 0.75 mg
• Usual replacement dosages: hydrocortisone about 25 mg/day, prednisone about 5 mg/day, dexamethasone about 0.5 mg/day

13.2 Hydrocortisone vs. Prednisone

When to Choose Hydrocortisone:

• Primary adrenal insufficiency: Hydrocortisone preferred due to mineralocorticoid activity
• Pediatric patients: Shorter half-life allows better dose titration and growth monitoring
• Patients requiring physiologic cortisol rhythm: Divided dosing better replicates circadian rhythm
• Pregnancy: Hydrocortisone preferred (more safety data, physiologic hormone)

When to Consider Prednisone:

• Secondary/tertiary adrenal insufficiency: Mineralocorticoid function intact, so longer-acting glucocorticoid acceptable
• Adherence concerns: Once-daily dosing improves compliance in some patients
• Cost sensitivity: Prednisone may be slightly less expensive in some settings (though both very affordable)
• Concurrent inflammatory condition: Longer-acting anti-inflammatory effect may be desirable

Clinical Considerations:

• Prednisone must be converted to active prednisolone in liver; severe liver disease may impair activation
• Hydrocortisone-to-prednisone ratio approximately 4:1 (e.g., hydrocortisone 20 mg daily ≈ prednisone 5 mg daily)
• Both effective; choice based on patient-specific factors

13.3 Modified-Release vs. Immediate-Release Hydrocortisone

Immediate-Release Hydrocortisone:

Advantages:

• Inexpensive (generic widely available)
• Flexible dosing (can split tablets, adjust individual doses)
• Decades of clinical experience
• Universally available

Disadvantages:

• Requires 2-3 daily doses (adherence challenge)
• Non-physiologic cortisol profile (sharp peaks after doses, low troughs overnight)
• May contribute to metabolic complications and suboptimal quality of life

Modified-Release Hydrocortisone (Plenadren, Chronocort):

Advantages:

• Once-daily dosing (improved convenience, potentially better adherence)
• More physiologic cortisol profile (gradual rise in morning, decline throughout day)
• Modest metabolic benefits (weight, blood pressure) in some studies

Disadvantages:

• Significantly more expensive (10-20× cost of immediate-release)
• Limited availability (not widely available in United States)
• Cannot adjust individual doses (fixed-dose tablet)
• Lower bioavailability requires dose conversion
• Long-term outcomes data still limited

Recommendations:

• First-line: Immediate-release hydrocortisone for most patients (cost-effective, flexible, well-established)
• Consider modified-release for:
  • Patients with adherence difficulties due to multiple daily dosing
  • Metabolic complications (obesity, hyperglycemia) not controlled with dose optimization
  • Strong patient preference for once-daily dosing and willing to pay higher cost
  • Participation in clinical trial or research setting

13.4 Oral vs. Injectable Formulations

Oral Hydrocortisone (Tablets, Oral Solution):

Advantages:

• Convenient for chronic replacement therapy
• High bioavailability (96%)
• Easy dose titration
• Widely available, inexpensive

Disadvantages:

• Requires GI absorption (ineffective if vomiting, severe diarrhea, malabsorption)
• Cannot be used in unconscious patients
• Slower onset of action (peak at 1-2 hours)

Injectable Hydrocortisone (Solu-Cortef®):

Advantages:

• Immediate bioavailability (100% by definition)
• Essential for adrenal crisis, vomiting, or unconscious patients
• Faster onset of action

Disadvantages:

• Requires IV/IM administration (not practical for daily use)
• More expensive
• Short duration without continuous infusion

Clinical Use:

• Oral: Daily replacement therapy in stable patients
• Injectable: Adrenal crisis, pre-/peri-operative stress dosing, patients unable to take oral medications
• Patient education: All patients with adrenal insufficiency should have injectable hydrocortisone at home for emergencies

13.5 Hydrocortisone vs. Fludrocortisone

Not Direct Alternatives (Often Used Together):

Hydrocortisone:

• Primary glucocorticoid effect
• Moderate mineralocorticoid activity (1:1 ratio)
• At replacement doses (15-25 mg daily), provides partial but usually insufficient mineralocorticoid replacement

Fludrocortisone:

• Potent mineralocorticoid (125× more potent than hydrocortisone for mineralocorticoid effect)
• Minimal glucocorticoid activity at typical doses (0.05-0.2 mg daily)
• Use: Supplemental mineralocorticoid replacement in primary adrenal insufficiency

Clinical Practice in Primary Adrenal Insufficiency:

• Most patients require both hydrocortisone and fludrocortisone
• Hydrocortisone dose based on glucocorticoid need
• Fludrocortisone dose titrated to maintain blood pressure, normalize electrolytes, and achieve renin in upper normal range

Secondary/Tertiary Adrenal Insufficiency:

• Mineralocorticoid function (aldosterone) intact
• Hydrocortisone alone sufficient (fludrocortisone not needed)

14. Storage and Handling

14.1 Storage Conditions

Oral Tablets (Immediate-Release):

Temperature:

• Store at controlled room temperature: 20°C to 25°C (68°F to 77°F)
• Excursions permitted to 15-30°C (59-86°F)
• Avoid excessive heat (>40°C/104°F)

Moisture Protection:

• Keep in tightly closed container
• Protect from moisture
• Do not store in bathroom (humidity can degrade medication)

Light Protection:

• Store in original container or amber pharmacy bottle
• Protect from light exposure
• Prolonged light exposure may reduce potency

Stability:

• Shelf life: Typically 2-3 years from manufacture date if stored properly
• Check expiration date; do not use expired medication

KHINDIVI® Oral Solution:

Storage:

• Store at controlled room temperature 20°C to 25°C (68°F to 77°F)
• Do not freeze
• Protect from light
• Discard open bottle per manufacturer instructions (typically 60 days after opening)

Handling:

• Shake well before each use
• Use provided oral syringe for accurate measurement

14.2 Injectable Formulations (Solu-Cortef®)

Unreconstituted Powder:

Storage Conditions:

• Store at controlled room temperature 20°C to 25°C (68°F to 77°F)
• Protect from light
• Do not freeze
• Shelf life: Check expiration date on vial

Reconstituted/Diluted Solutions:

Preparation:

• Reconstitute with sterile water for injection or 0.9% sodium chloride injection as per package insert
• Gentle swirling (not vigorous shaking) to dissolve powder

Storage After Reconstitution:

• Store reconstituted/diluted solution at controlled room temperature 20°C to 25°C and protect from light
• Use within 12 hours if stored at room temperature
• Use within 24 hours if refrigerated (2-8°C)
• Discard unused solution after these time frames

Stability Research:

• Studies show elevated temperature (30°C) significantly reduced stability (t95% 4.6-6.3 hours)
• Storage below 30°C maintained stability for at least 6 hours with less than 5% degradation
• Bags stored at room temperature in light showed marginally higher degradation rates, suggesting light protection important

14.3 Patient Storage Recommendations

Home Storage:

• Keep medication in cool, dry place away from direct sunlight
• Bedroom dresser or kitchen cabinet (not above stove) suitable
• Avoid bathroom medicine cabinet (temperature and humidity fluctuations)
• Child-resistant containers if children in household

Travel Storage:

• Carry medication in carry-on luggage (not checked baggage) to avoid temperature extremes
• Keep in original labeled container for airport security
• Bring extra supply in case of travel delays
• Carry letter from physician documenting need for medication and injectable emergency supply

Emergency Injectable Storage:

• Store Solu-Cortef Act-O-Vial at room temperature in readily accessible location
• Check expiration date every 6 months; replace before expiration
• Consider storing one vial at home and one in car/workplace for accessibility
• Ensure family members know location

Compounded Liquid Formulations:

• Follow pharmacy-specific storage instructions (vary by formulation and preservatives)
• Refrigeration may be required for some compounded suspensions
• Note expiration date (often shorter than commercial products, e.g., 30-90 days)

14.4 Signs of Degradation

Visual Inspection:

• Tablets: Discard if discolored, crumbling, or have unusual odor
• Injectable solution after reconstitution: Should be clear to slightly yellow; discard if cloudy, contains particulates, or is discolored

Potency Concerns:

• If medication has been exposed to excessive heat, light, or moisture, potency may be reduced
• When in doubt, obtain fresh supply from pharmacy
• Never use medication past expiration date

14.5 Disposal

Unused or Expired Medication:

• Preferred: Drug take-back programs (pharmacies, DEA-sponsored events)
• Alternative: FDA-approved disposal instructions:
  • Mix tablets with undesirable substance (coffee grounds, cat litter) in sealed plastic bag
  • Throw in household trash
  • Remove personal information from prescription label before discarding container
• Do NOT flush down toilet or drain (environmental concerns)

Used Injectable Supplies:

• Dispose of needles and syringes in FDA-cleared sharps container
• If sharps container not available, use heavy-duty plastic container (laundry detergent bottle) with secure lid
• Label "Used Sharps - Do Not Recycle"
• Follow local regulations for sharps disposal

15. Goal Archetype Integration

15.1 Adrenal Insufficiency Replacement Archetype

Hydrocortisone serves as the cornerstone of the Adrenal Insufficiency Replacement goal archetype, targeting individuals who require lifelong glucocorticoid replacement due to inadequate endogenous cortisol production.

Primary Goal Characteristics:

Restoration of Physiologic Function:

• Replace the body's inability to produce adequate cortisol
• Maintain normal metabolic, immune, and cardiovascular homeostasis
• Enable normal stress response through appropriate stress dosing protocols
• Support quality of life comparable to healthy individuals

Target Population Profiles:

• Primary Adrenal Insufficiency (Addison's Disease): Autoimmune destruction, bilateral adrenalectomy, infectious causes
• Secondary Adrenal Insufficiency: Pituitary ACTH deficiency from tumors, surgery, radiation, or Sheehan syndrome
• Tertiary Adrenal Insufficiency: Hypothalamic dysfunction or iatrogenic suppression from chronic exogenous glucocorticoid use
• Congenital Adrenal Hyperplasia (CAH): Enzymatic defects requiring both replacement and ACTH suppression

Archetype-Specific Dosing Philosophy:

• Minimally Effective Dose: Unlike pharmacologic anti-inflammatory use, replacement therapy targets the lowest dose that eliminates insufficiency symptoms without causing excess
• Circadian Rhythm Alignment: Dosing schedule mimics physiologic cortisol secretion (morning peak, evening nadir)
• Individualized Titration: Clinical symptoms guide dosing rather than rigid adherence to population-based recommendations

15.2 Physiologic Cortisol Replacement Archetype

The Physiologic Cortisol archetype represents a precision medicine approach to glucocorticoid replacement, emphasizing replication of endogenous cortisol patterns.

Core Principles:

Circadian Rhythm Fidelity:

• Endogenous cortisol peaks at 6-8 AM (awakening response) with levels of 10-20 mcg/dL
• Nadir occurs at midnight with levels of <5 mcg/dL
• Immediate-release hydrocortisone given 2-3 times daily approximates but does not fully replicate this pattern
• Modified-release formulations and subcutaneous infusion more closely mirror physiologic secretion

Cortisol Exposure Optimization:

• Area Under the Curve (AUC): Target physiologic cortisol exposure without excessive peaks or prolonged troughs
• Peak-to-Trough Ratio: Avoid the supraphysiologic peaks of immediate-release dosing that may contribute to metabolic complications
• Overnight Exposure: Minimize late evening cortisol to preserve physiologic overnight nadir (important for metabolic health and sleep quality)

Goal Achievement Markers:

• Resolution of fatigue, weakness, and orthostatic symptoms
• Normalization of blood pressure without hypertension
• Stable weight without central adiposity
• Normal glucose tolerance
• Adequate bone mineral density
• Normal quality of life scores

15.3 Stress Response Preservation Archetype

A critical component of hydrocortisone replacement is preserving the ability to respond to physiologic stressors through appropriate dose escalation.

Archetype Framework:

Anticipatory Stress Coverage:

• Pre-operative stress dosing for surgical procedures
• Dental procedure coverage for invasive work
• Planned physical exertion (marathon running, extreme sports) may require increased doses

Reactive Stress Adaptation:

• Sick Day Rules: Systematic dose escalation during illness
• Trauma Response: Immediate emergency dosing protocols
• Emotional Stress: Recognition that severe psychological stress may require modest dose increase

Self-Management Competency Goals:

• Patient independently recognizes stress situations requiring dose adjustment
• Confidence in self-administering emergency injectable hydrocortisone
• Family/caregiver training for unconscious patient scenarios
• Appropriate medical alert identification worn at all times

16. Age-Stratified Dosing

16.1 Neonates and Infants (0-12 months)

Physiologic Considerations:

• Higher metabolic clearance per body surface area than older children/adults
• Immature hepatic enzyme systems may paradoxically reduce metabolism
• Critical period for brain development; both deficiency and excess are harmful
• Frequent feeding schedules affect cortisol requirements

Dosing Recommendations:

• Replacement dose: 10-15 mg/m²/day in 3-4 divided doses
• Formula: Calculate body surface area (BSA) using Mosteller formula: BSA (m²) = sqrt[(height (cm) × weight (kg)) / 3600]
• Timing: Align with feeding schedule; larger dose with morning feed

Formulation Considerations:

• KHINDIVI oral solution (5 mg/mL) preferred for precise dosing
• Compounded suspensions acceptable from quality-controlled pharmacies
• Tablets cannot be accurately split for doses <2.5 mg

Monitoring:

• Weight gain and linear growth (plot on WHO growth charts)
• Developmental milestones
• Signs of under-replacement: Poor feeding, lethargy, hypoglycemia, failure to thrive
• Signs of over-replacement: Excessive weight gain, poor linear growth

16.2 Children (1-12 years)

Dosing Framework:

• Standard replacement: 8-10 mg/m²/day in 3 divided doses
• CAH: 10-15 mg/m²/day (higher end for androgen suppression)
• Typical total daily doses by age:
  • 1-3 years: 5-10 mg/day
  • 4-6 years: 7.5-15 mg/day
  • 7-12 years: 10-20 mg/day

Growth-Preserving Strategies:

• Use lowest effective dose that controls symptoms and (in CAH) suppresses androgens
• Avoid late evening doses that suppress overnight growth hormone secretion
• Monitor height velocity every 3-6 months; plot on growth charts
• If growth deceleration occurs, reduce dose if clinically tolerated
• Consider modified-release formulations to minimize cortisol peaks

Stress Dosing for Children:

• Minor illness (cold, mild fever): Double usual daily dose
• Moderate illness (gastroenteritis, fever >38.5°C): 50-75 mg/m²/day
• Severe stress/surgery: 100 mg/m² IV bolus, then 100 mg/m²/day continuous or divided q6h

Transition Planning:

• Begin discussing self-management at age 10-12
• Introduce concepts of stress dosing and emergency protocols
• Consider summer camp or school-based diabetes education models for self-care training

16.3 Adolescents (12-18 years)

Dosing Considerations:

• Puberty increases cortisol requirements; may need dose increase during growth spurt
• Typical range: 15-25 mg/day (approaching adult doses)
• Body surface area calculations remain useful through mid-adolescence
• Transition to weight-based or fixed adult dosing by late adolescence

Adherence Challenges:

• Adolescence associated with peak medication non-adherence
• Twice-daily dosing may improve compliance vs. three-times-daily
• Modified-release once-daily formulations attractive option for adherence
• Peer relationships, body image concerns may influence medication-taking behavior

Special Considerations:

• Female adolescents with CAH: Monitor for menstrual irregularities, hirsutism, acne indicating androgen excess
• Male adolescents with CAH: Monitor for testicular adrenal rest tumors
• Sports participation: Athletes may need stress dosing for intensive training/competition

Transition to Adult Care:

• Begin planning at age 14-16
• Ensure patient can independently:
  • Describe their condition and treatment
  • Recognize signs of under/over-replacement
  • Implement sick day rules
  • Self-administer emergency injection
• Formal transition to adult endocrinology by age 18-21

16.4 Adults (18-65 years)

Standard Dosing:

• Replacement range: 15-25 mg/day (guideline midpoint 20 mg; clinical practice mean ~14 mg)
• Distribution:
  • Two-dose regimen: 15 mg upon waking, 5 mg early afternoon (2-4 PM)
  • Three-dose regimen: 10 mg upon waking, 5 mg noon, 5 mg late afternoon (not after 6 PM)

Dose Individualization:

• Start at 20 mg/day and titrate based on clinical response
• Active individuals, high-stress occupations may need higher doses
• Sedentary individuals, those with obesity may tolerate lower doses
• Menstruating women may note cyclical symptom variations

Occupational Considerations:

• Shift workers require dosing schedule adjustment to match their sleep-wake cycle
• "Morning dose" = dose upon waking, regardless of clock time
• High-physical-demand occupations (construction, military) may need higher baseline or stress dosing
• Healthcare workers with unpredictable schedules need flexible dosing strategies

16.5 Older Adults (>65 years)

Age-Related Physiologic Changes:

• Decreased hepatic clearance may reduce hydrocortisone metabolism
• Reduced cortisol-binding globulin increases free cortisol fraction
• Increased sensitivity to glucocorticoid side effects
• Comorbidities (diabetes, osteoporosis, hypertension) more prevalent

Dosing Adjustments:

• Start low: Begin at 15 mg/day (lower end of range)
• Titrate slowly: Increase in 2.5 mg increments with 2-4 week intervals
• Monitor closely: More frequent assessment for over-replacement signs

Enhanced Adverse Effect Surveillance:

• Osteoporosis: Baseline DEXA; calcium 1200-1500 mg/day, vitamin D 800-2000 IU/day; bisphosphonate if T-score <-2.5
• Hyperglycemia: Fasting glucose and HbA1c every 6 months; lower threshold for intervention
• Hypertension: Home BP monitoring; minimize fludrocortisone dose if hypertensive
• Cognitive effects: Monitor for confusion, delirium, especially during stress dosing
• Falls risk: Assess gait, balance; physical therapy referral for myopathy signs

Polypharmacy Considerations:

• Review for CYP3A4 interactions (see Section 17)
• Coordinate with primary care and specialists managing comorbidities
• Pill burden and complex regimens may affect adherence

17. Drug Interactions (Expanded)

17.1 CYP3A4-Mediated Interactions (Clinical Focus)

High-Risk CYP3A4 Inducers:

High-Risk CYP3A4 Inhibitors:

17.2 Hormone Therapy Interactions

Estrogen-Containing Therapies:

• Mechanism: Estrogen increases cortisol-binding globulin (CBG) synthesis, reducing free cortisol fraction
• Affected therapies: Oral contraceptives, hormone replacement therapy (HRT), estradiol patches
• Clinical impact: May require hydrocortisone dose increase (typically 20-30%)
• Monitoring: Reassess symptoms 4-6 weeks after starting/stopping estrogen

Thyroid Hormone:

• Critical interaction: Thyroid hormone increases cortisol clearance
• Clinical scenario: Patient with undiagnosed adrenal insufficiency started on levothyroxine → adrenal crisis
• Management: Always evaluate adrenal function before initiating thyroid replacement in hypopituitarism
• Dose adjustment: Patients starting levothyroxine may need hydrocortisone dose increase

Growth Hormone:

• Mechanism: GH inhibits 11β-HSD1, reducing cortisol regeneration from cortisone
• Clinical impact: Starting GH therapy in patient with subclinical adrenal insufficiency may unmask deficiency
• Management: Reassess hydrocortisone needs when initiating or discontinuing GH

17.3 Cardiovascular Drug Interactions

Antihypertensives:

• Hydrocortisone may reduce efficacy of all antihypertensive classes
• ACE inhibitors/ARBs: May need dose increase; monitor potassium (opposing effects on K+)
• Beta-blockers: Monitor for breakthrough hypertension
• Diuretics: See potassium section below

Potassium-Affecting Drugs:

• Additive hypokalemia risk with:
  • Loop diuretics (furosemide, bumetanide)
  • Thiazide diuretics (hydrochlorothiazide, chlorthalidone)
  • Amphotericin B
  • High-dose beta-agonists (albuterol nebulizers)
• Monitoring: Serum potassium every 3-6 months; more frequently with diuretics
• Management: Potassium supplementation or potassium-sparing diuretic (amiloride, spironolactone) if persistent hypokalemia

Anticoagulants:

• Warfarin: Variable effect; may increase or decrease INR; monitor weekly when initiating HC
• DOACs: Limited data; theoretical increased bleeding risk from GI effects
• Aspirin: Corticosteroids may reduce salicylate levels; monitor if high-dose aspirin

17.4 Diabetes Medication Interactions

All Antidiabetic Agents:

• Hydrocortisone antagonizes glucose-lowering effects
• Expect worsened glycemic control when initiating or increasing HC
• May need to increase antidiabetic medication doses by 10-30%

Specific Considerations:

17.5 Immunosuppressant Interactions

Calcineurin Inhibitors (Cyclosporine, Tacrolimus):

• Hydrocortisone (high doses) induces CYP3A4, potentially lowering CNI levels
• At replacement doses, effect is minimal
• Monitor CNI levels when adjusting hydrocortisone dose significantly

Mycophenolate:

• No significant pharmacokinetic interaction
• Additive immunosuppression; infection risk monitoring

17.6 Gastrointestinal Drug Interactions

NSAIDs:

• Major interaction: 4-fold increased GI bleeding risk
• Management:
  • Avoid concurrent use if possible
  • If necessary: PPI prophylaxis (omeprazole, pantoprazole)
  • Use lowest NSAID dose for shortest duration
  • Consider COX-2 selective agents (celecoxib) if NSAID needed

Proton Pump Inhibitors:

• No effect on hydrocortisone absorption
• Recommended for patients requiring chronic NSAID therapy

18. Bloodwork Impact

18.1 Cortisol Level Interpretation During Therapy

Critical Concept: Serum Cortisol Monitoring is NOT Useful for Routine Dose Adjustment

Why Serum Cortisol is Unreliable:

• Cortisol levels fluctuate dramatically after each hydrocortisone dose
• Timing of blood draw relative to dose makes interpretation impossible
• Peak levels occur 1-2 hours post-dose (may appear "high")
• Trough levels before next dose (may appear "low")
• Clinical assessment is superior to biochemical monitoring

When Cortisol Levels ARE Useful:

• Diagnosis: Morning cortisol <3 mcg/dL confirms insufficiency; >15 mcg/dL excludes it
• Cortisol day curve: Serial samples to assess 24-hour cortisol profile (research/specialized centers)
• Suspected malabsorption: Document adequate absorption with timed post-dose levels

Salivary Cortisol:

• Measures free (unbound) cortisol
• Not affected by CBG changes (pregnancy, estrogen therapy, liver disease)
• Useful for assessing late-night cortisol (should be low at physiologic replacement doses)
• May detect evening over-exposure from poorly timed afternoon doses

18.2 ACTH Monitoring

Primary Adrenal Insufficiency:

• ACTH levels typically elevated (>100 pg/mL) at diagnosis
• With adequate replacement, ACTH may decrease but rarely normalizes
• Monitoring use: Persistently very elevated ACTH (>300 pg/mL) despite treatment suggests under-replacement
• Frequency: Not routinely monitored; consider if clinical concern for inadequate dosing

Secondary/Tertiary Adrenal Insufficiency:

• ACTH levels low or low-normal at baseline
• Cannot use ACTH to monitor replacement adequacy (already deficient)

Congenital Adrenal Hyperplasia (CAH):

• ACTH drives adrenal androgen production
• Monitor 17-hydroxyprogesterone (17-OHP) and androstenedione as surrogates for ACTH-driven pathway
• Targets:
  • 17-OHP: 400-1200 ng/dL (morning, pre-dose)
  • Androstenedione: Upper normal for age/sex
• Levels too low indicate over-replacement (growth suppression risk)
• Levels too high indicate under-replacement (virilization risk)

18.3 Electrolyte Monitoring

Sodium and Potassium:

• Primary AI: Monitor every 3-6 months
• Secondary/Tertiary AI: Less critical (mineralocorticoid function intact) but annual check reasonable
• Interpretation:
  • Persistent hyponatremia: Inadequate glucocorticoid replacement
  • Hyperkalemia: Inadequate fludrocortisone (primary AI)
  • Hypokalemia: Excessive fludrocortisone or over-replacement

Renin (Plasma Renin Activity or Direct Renin):

• Primary AI only: Guides fludrocortisone dosing
• Target: Upper half of normal range
• Elevated renin → increase fludrocortisone
• Suppressed renin → decrease fludrocortisone
• Frequency: Every 6-12 months or when adjusting fludrocortisone

18.4 Metabolic Monitoring

Glucose and HbA1c:

• Frequency: Every 6-12 months (more often if diabetic or prediabetic)
• Interpretation:
  • Rising HbA1c may indicate over-replacement or need for better glycemic management
  • Hypoglycemia (especially in children) may indicate under-replacement

Lipid Panel:

• Frequency: Annually
• Interpretation: Dyslipidemia may worsen with over-replacement; treat per cardiovascular guidelines

Liver Function Tests:

• Not routinely affected by replacement-dose hydrocortisone
• Consider baseline and periodic monitoring if concerns about hepatic metabolism

18.5 Bone Health Markers

DEXA Scan (Bone Mineral Density):

• Baseline: All patients at risk (postmenopausal women, men >50, prior fracture, long-term therapy)
• Frequency:
  • Normal BMD: Every 3-5 years
  • Osteopenia: Every 1-2 years
  • Osteoporosis: Annually while on treatment

Bone Turnover Markers (CTx, P1NP):

• Not routinely recommended
• May be useful in research settings or to monitor treatment response

18.6 Optimal Blood Draw Timing

For Diagnostic Purposes (Before Starting Treatment):

• Morning cortisol: Draw at 8 AM (fasting)
• ACTH: Draw simultaneously with cortisol

For Monitoring During Therapy:

• Electrolytes/Glucose: Any time (fasting preferred for glucose)
• Renin: Morning, fasting, after patient has been upright for 30 minutes
• 17-OHP (CAH): Early morning before first hydrocortisone dose
• Cortisol (if needed): Document exact time of last dose; interpret in context

19. Protocol Integration

19.1 Circadian Dosing Protocols

Standard Immediate-Release Protocol:

Two-Dose Regimen (Preferred for Most Patients):

Three-Dose Regimen (For Persistent Afternoon Fatigue):

Modified-Release Protocol (Plenadren):

Subcutaneous Infusion Protocol (CSHI):

19.2 Sick Day Rules Protocol

Patient Education Handout Framework:

Level 1: Minor Illness (Cold, Mild Fever, Minor Injury)

• Criteria: Able to eat and drink, temperature <38°C (100.4°F), functioning normally aside from illness symptoms
• Action: Double your usual daily dose
• Duration: Continue doubled dose until illness resolves (typically 2-3 days)
• Example: If usual dose is 20 mg/day → take 40 mg/day (20 mg morning, 10 mg noon, 10 mg afternoon)

Level 2: Moderate Illness (Flu, Gastroenteritis, Fever >38°C)

• Criteria: Fever, vomiting/diarrhea, unable to eat normally, feeling significantly unwell
• Action: Triple your usual daily dose
• Duration: Until symptoms significantly improve
• Example: If usual dose is 20 mg/day → take 60 mg/day
• Vomiting protocol: If you vomit within 30 minutes of taking hydrocortisone:
  • Wait 30 minutes
  • Take another dose
  • If you vomit again, INJECT your emergency hydrocortisone and go to ER

Level 3: Severe Illness/Unable to Take Oral Medication

• Criteria: Persistent vomiting, severe illness, altered consciousness, trauma
• Action:
  1. INJECT 100 mg hydrocortisone IM immediately
  2. Call 911 or go directly to emergency room
  3. DO NOT wait to see if you improve

Emergency Injection Instructions:

1. Remove cap from Solu-Cortef Act-O-Vial
2. Press down on plunger to mix powder with liquid
3. Shake gently until dissolved
4. Draw solution into syringe
5. Inject into outer thigh muscle (through clothing if necessary)
6. Seek immediate medical attention

19.3 Surgical Stress Protocol

Pre-Operative Assessment:

• Confirm adrenal insufficiency diagnosis and current hydrocortisone dose
• Document stress dosing protocol in pre-operative orders
• Ensure anesthesiologist and surgeon are aware of diagnosis
• Have IV hydrocortisone available in OR

Surgical Stress Dosing by Procedure Type:

Post-Operative Taper Example (Major Surgery):

19.4 Labor and Delivery Protocol

Antepartum Management:

• Continue usual hydrocortisone replacement throughout pregnancy
• Some experts recommend 20-30% dose increase in third trimester (controversial)
• Ensure obstetric team aware of diagnosis; document stress dosing plan in chart

Labor Stress Dosing:

Cesarean Section:

• Follow major surgery protocol
• 100 mg IV at induction of anesthesia
• 50 mg IV q6-8h for 24-48 hours
• Taper to usual oral dose over 2-3 days

19.5 Exercise and Athletic Performance Protocol

Routine Exercise:

• Usual hydrocortisone dose adequate for moderate exercise (walking, light gym workout)
• Timing: Consider taking second dose 30-60 minutes before afternoon exercise if experiencing fatigue

Endurance Events (Marathon, Triathlon, Cycling Century):

• Pre-event: Increase morning dose by 5-10 mg on event day
• During event:
  • Carry extra hydrocortisone tablets
  • Take 5-10 mg every 2-3 hours for events >3 hours
  • Carry emergency injectable
• Post-event: Return to usual dose unless fatigue persists
• Recovery day: May need 1.5-2× usual dose

Competitive Athletes:

• Work with sports medicine physician and endocrinologist
• Therapeutic Use Exemption (TUE) required for competitive sports (hydrocortisone is prohibited substance at supraphysiologic doses)
• Document medical necessity and replacement dosing for TUE application

19.6 Travel Protocol

Time Zone Adjustment:

• <5 hour time change: Shift dosing schedule gradually over 1-2 days
• >5 hour time change: Reset to local time immediately
  • Take usual morning dose at local waking time
  • May need extra 5-10 mg if travel day is prolonged

Travel Checklist:

• Sufficient hydrocortisone tablets for trip + 50% extra
• Emergency injectable hydrocortisone (Solu-Cortef 100 mg)
• Syringes and needles for emergency injection
• Doctor's letter explaining diagnosis and medication need
• Medical alert identification
• Sick day rules card/instructions
• International SOS or travel medical assistance contact

Carry-On Requirements:

• ALL medications and injection supplies in carry-on luggage
• Keep in original pharmacy-labeled containers
• Liquids and syringes: May require documentation letter for TSA/security
• Consider splitting supplies between carry-on and checked bag (backup)

19.7 Integration with Other Hormone Replacement

Hypopituitarism (Multiple Hormone Deficiencies):

• Priority: Start hydrocortisone FIRST before other hormone replacement
• Why: Thyroid hormone and GH both increase cortisol clearance; starting them before cortisol replaced can precipitate adrenal crisis

Recommended Initiation Sequence:

1. First: Hydrocortisone (establish stable replacement over 1-2 weeks)
2. Second: Levothyroxine (after cortisol replacement established)
3. Third: Sex steroids (testosterone or estrogen)
4. Fourth: Growth hormone (last; unmasks/worsens adrenal insufficiency if added before HC)

Ongoing Coordination:

• Starting estrogen → may need to increase hydrocortisone dose (CBG increases)
• Starting levothyroxine → may need to increase hydrocortisone dose (clearance increases)
• Starting GH → monitor for unmasked adrenal insufficiency symptoms

References

1. DrugBank Online. (2025). Hydrocortisone: Uses, Interactions, Mechanism of Action. Retrieved from https://go.drugbank.com/drugs/DB00741

2. Drugs.com. (2024). Hydrocortisone. Retrieved from https://www.drugs.com/hydrocortisone.html

3. Drugs.com. (2024). Hydrocortisone Use During Pregnancy. Retrieved from https://www.drugs.com/pregnancy/hydrocortisone.html

4. National Library of Medicine. (2025). Hydrocortisone - Drugs and Lactation Database (LactMed®). Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK500976/

5. National Center for Biotechnology Information. (2024). Daily Glucocorticoid Replacement Dose in Adrenal Insufficiency, a Mini Review. PMC9276933. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9276933/

6. National Center for Biotechnology Information. (2018). Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study. PMC5425941. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC5425941/

7. National Center for Biotechnology Information. (2017). Comparison of hydrocortisone and prednisone in the glucocorticoid replacement therapy post-adrenalectomy of Cushing's Syndrome. PMC5739705. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC5739705/

8. PubMed. (1991). Pharmacokinetics and oral bioavailability of hydrocortisone. PMID: 2050835. Retrieved from https://pubmed.ncbi.nlm.nih.gov/2050835/

9. PubMed. (2014). Variation in absorption and half-life of hydrocortisone influence plasma cortisol concentrations. PMID: 25369980. Retrieved from https://pubmed.ncbi.nlm.nih.gov/25369980/

10. PubMed. (2014). Improving outcomes in patients with adrenal insufficiency: a review of current and future treatments. PMID: 24849526. Retrieved from https://pubmed.ncbi.nlm.nih.gov/24849526/

11. Pfizer Medical Information. (2024). SOLU-CORTEF® (hydrocortisone sodium succinate) Storage and Handling. Retrieved from https://www.pfizermedical.com/solu-cortef/storage-handling

12. Pfizer Medical Information Canada. (2024). SOLU-CORTEF Storage And Stability. Retrieved from https://www.pfizermedicalinformation.ca/en-ca/solu-cortef/storage-and-stability

13. American Academy of Family Physicians. (1998). A Different Look at Corticosteroids. American Family Physician, 58(2), 443-450. Retrieved from https://www.aafp.org/pubs/afp/issues/1998/0801/p443.html

14. ClinCalc. (2024). Corticosteroid Conversion Calculator. Retrieved from https://clincalc.com/corticosteroids/

15. Mayo Clinic. (2024). Hydrocortisone (oral route) - Side effects & dosage. Retrieved from https://www.mayoclinic.org/drugs-supplements/hydrocortisone-oral-route/description/drg-20075259

16. Sage Journals. (2019). Novel insights into glucocorticoid replacement therapy for pediatric and adult adrenal insufficiency. Therapeutic Advances in Endocrinology and Metabolism. Retrieved from https://journals.sagepub.com/doi/10.1177/2042018818821294

17. ScienceDirect. (2018). Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM). The Lancet Diabetes & Endocrinology, 6(3), 173-185. Retrieved from https://www.sciencedirect.com/science/article/abs/pii/S2213858717303984

18. ScienceDirect. (2025). Continuous Subcutaneous Hydrocortisone Infusion in Adrenal Insufficiency: Practical Experience in 33 Subjects. Clinical Endocrinology. Retrieved from https://www.sciencedirect.com/science/article/abs/pii/S1530891X25001466

19. National Center for Biotechnology Information. (2024). Stability of Hydrocortisone in Oral Powder Form Compounded for Pediatric Patients in Japan. PMC8400744. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8400744/

20. ScienceDirect. (2005). Shelf lives of aseptically prepared medicines – stability of hydrocortisone sodium succinate in PVC and non-PVC bags and in polypropylene syringes. Pharmaceutical Technology in Hospital Pharmacy, 5(2), 37-43. Retrieved from https://www.sciencedirect.com/science/article/abs/pii/S0731708505000129

Document Information:

• Title: Hydrocortisone - Comprehensive Research Paper
• Subject: Glucocorticoid Replacement Therapy
• Total Length: Approximately 28,000 words
• Sections: 14 comprehensive sections plus references
• Last Updated: December 2024
• Intended Audience: Healthcare professionals, researchers, patients with adrenal insufficiency